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Abstract
Kwei-Yu Liu. Ph.D. The University of Memphis. December 2019. Development of
Multilayered Micelles and Hydrogels for Drug/Gene Delivery Systems. Major Professor:
Tomoko Fujiwara, Ph.D.
In recent years, polymeric drug vehicles which respond to external stimuli have
attracted extensive attention for delivering their therapeutic payloads at targeted locations
and with controlled timing. To realize these ‘smart’ delivery systems, our strategy is to
design polymeric micelles with multilayered morphologies and stimuli-responsive
properties as a drug carrier. In this dissertation, the development of two types of drug
delivery systems are described.
The first approach focuses on a hydrogel system prepared from DNA-loaded
three-layered micelles (3LM) composed of biodegradable block copolymers. The 3LM
possess great stability under physiological conditions and release DNA in slightly acidic
conditions. In this study, 3LM were utilized to achieve thermo-responsive, injectable
hydrogel systems for localized gene delivery. Specifically, the structure, stability,
mechanical strength, sol-to-gel transition mechanism, and degradation behavior of the
hydrogels were analyzed. In vitro studies of the DNA-loaded hydrogels were further
discussed for gene delivery capability.
The second approach was to design multilayered micelles incorporating
poly(amino acid) segments to explore novel mechanisms for efficient drug delivery. We
hypothesized that biocompatible poly(amino acid)s would be capable of forming selfassembled micelles via electrostatic interactions and respond to a variety of stimuli
including changes in pH, dilution, and salt concentrations. The resulting micelles were
characterized and evaluated for drug delivery capabilities.
iv

PREFACE
Chapter 2 is modified from the peer-reviewed journal article published in
Polymers, 2019, 11(5), 796, entitled, “Characterization and Optimization of PLA
Stereocomplexed Hydrogels for Local Gene Delivery Systems”. The degradation study
detailed in Chapter 2 was performed with Elisabeth Rachel Wiley, an undergraduate
trainee. The 3LM micelle hydrogel approach was initially developed by Dr. Daniel
Abebe, and the data for dynamic light scattering, rheology, and wide angle X-ray
scattering were all collected by Dr. Abebe.

v

Table of Contents
Chapter

Page

List of Tables

ix

List of Figures

x

List of Schemes

xii

Abbreviations

xiii

1

2

Introduction

1

1.1 Drug Delivery Systems

1

1.1.1 Drug delivery mechanisms

2

1.1.2 Polymer-drug conjugates

4

1.1.3 Micro- and nanoparticles

9

1.1.4 Ion complexes

11

1.1.5 Complex copolymer micelles

12

1.1.6 Hydrogels

14

1.2 Scope and Outline of the Dissertation

16

Characterization and Optimization of PLA Stereocomplexed Hydrogels for
Local Gene Delivery Systems

18

2.1. Introduction

18

2.2. Materials and Methods

20

2.2.1. Materials

21

2.2.2. Measurements

21

2.2.3. Synthesis of triblock copolymers

22

2.2.4. DNA loaded 3LM micelle preparation

23

2.2.5. Stereocomplexed hydrogel preparation

24

2.2.6. Hydrogel degradation

25

vi

2.3. Results and Discussion

3

25

2.3.1. Synthesis of block copolymers

25

2.3.2. 3LM and hydrogel formation

27

2.3.3. Effect of formulation on micelle size and composition

27

2.3.4. Gelation mechanism and sol-to-gel phase transition

29

2.3.5. Mechanical strength

33

2.3.6. Effect of PEG block length on the hydrogels

35

2.3.7. Hydrogel degradation study

36

2.3.8. Hydrogel analysis by solid-state NMR

39

2.3.9. Gene delivery prospectives of 3LM-hydrogels

42

2.4. Conclusions

43

Multilayered Micelles Containing Poly(Aspartic acid) and Poly(Lysine) for
Drug Delivery

44

3.1. Introduction

44

3.2. Experimental

47

3.2.1. Material

47

3.2.2. N-carboxyanhydride (NCA) synthesis

48

3.2.2.1. Synthesis of N-carboxyanhydride -benzyl-L-aspartate
(NCA-BLA)
48
3.2.2.2. Synthesis of N-carboxyanhydride N-benzyloxycarbonyl-L-lysine (NCA-Lys(Z))

48

3.2.2.3 Synthesis of N-carboxyanhydride O-tert-butyl-L-serine
(NCA-Ser(tBu))
49
3.2.3. Polymer synthesis

49

3.2.3.1. poly(Lys(Z))-PEG-poly(Lys(Z))

49

3.2.3.2. poly(Lys)-PEG-poly(Lys)

49

3.2.3.3. PLA-NH2

50

3.2.3.4. PLA-poly(-benzyl-L-aspartate) (PLA-poly(BLA))

50

3.2.3.5. PLA-poly(L-aspartic acid)(PLA-poly(Asp))

51

3.2.4. Nanoparticle preparation
vii

51

3.2.4.1 Nanoparticle prepared by an emulsion method

51

3.2.4.2 Drug encapsulation efficiency

51

3.2.5. Instrumentation

51

3.3. Result and Discussion

52

3.3.1. NCA monomer synthesis

52

3.3.2. Micelle design-1

55

3.3.3. Micelle design-2

57

3.3.3.1. PLA-poly(Asp) Synthesis

57

3.3.3.2. PEG-poly(Lys) and poly(Lys)-PEG-poly(Lys) synthesis 61

4

3.3.3.3. Micelle formation

62

3.3.3.4. Flower micelle formation

64

3.3.3.5. Emulsion preparation

65

3.3.3.6. Drug encapsulation

66

3.4. Conclusion

68

Conclusion and Outlook

70

References

72

viii

LIST OF TABLES
Table

Page

1.1

List of DDS studies using pH- and redox-sensitive drug release
mechanisms

5

2.1

Composition ratios of inner:outer polymers in 3LM and mixed PEG
block sizes in D-micelles

29

2.2

Comparison of so-to-gel transition and stability of 10 wt%
stereocomplexed hydrogels using D-micelles with mixed PEG length
(inner:outer of 3LM kept 1/5)

36

2.3

List of biological evaluations previously reported for 3LM and
stereocomplexed hydrogels.

42

3.1

Drug encapsulation comparison among emulsion, micelle, and micelle
design 2

67

ix

LIST OF FIGURES
Figure

Page

1.1

Drug delivery system through passive and active systems.

3

1.2

Typical stimuli-responsive functional groups.

5

1.3

a) Strategy to conjugate PTX onto polymer. B) PTX was conjugated
onto a linker on poly(Lys) side chain with ester bonds
PTX drugs were conjugated onto poly(Asp) though hydrazone
conjugation.

7

1.5

Hydrazone conjugation of Dox on polymer chain.

9

1.6

Various design of drug delivery system.

10

2.1

Schematic representation of 3LM and hydrogel components.

27

2.2

DLS intensity analysis of: (a) 3LM compositions prepared by different
weight ratios of PLLA-PEI-PLLA (inner layer) and PLLA-PEG-PLLA
(outer layer); (b) 3LM sizes at inner;outer ratio 1:1, but different
PLLA block length of outer block copolymers.

29

2.3

WAXD profiles of hydrogels prepared mixing the following micelles
with PDLA-PEG-PDLA micelles: (a) 3LM using PDLLA-PEGPDLLA (racemic polymer) outer layer; (b) typical 3LM from PLLAPEG-PLLA outer layer; and (c) simple PLLA-PEG-PLLA micelles.

31

2.4

Sol-to-Gel phase diagram: variation of: (a) total polymer
concentrations with constant 3LM inner:outer = 1/1; and (b) 3LM
composition of inner:outer ratios with constant polymer concentration
at 20 wt% (open square: solution state, closed triangle: gel state by tilt
method).

33

2.5

Summary of so-to-gel phase diagram.

33

2.6

Rheological properties with (a) time and (b) frequency plots for the
stereocomplex hydrogels prepared using 3LM with different
inner:outer polymer ratios and the PLLA-PEG-PLLA micelle.

35

2.7

Schematic illustration of D-micelles with mixed PEG block length.

35

2.8

Weight loss of 3LM-hydrogels in pH 7.4 and pH 4.5 at 37°C in the
presence of proteinase K.

37

1.4

x

8

Figure

Page

2.9

GPC profiles of the supernatants at (a) pH 7.4 and (b) pH 4.5, after
lyophilized and re-dissolved in THF.

39

2.10

1

H NMR spectra of the lyophilized supernatants from the samples: pH
4.5, after 1day (blue), pH 4.5, after 7 day (red), and pH 7.4, after 7days
(green).

41

2.11

Solid-state 13C NMR spectra of (a) the PLLA-PEG-PLLA polymer,
and hydrogels from L- and D-micelles with (b) rapid and (c) slow
dehydration process, and hydrogels after 5 days degradation tests at (d)
pH 7 and (e) pH 4.5.

41

3.1

NMR spectrum of NCA monomer in DMSO a)NCA-BLA; b)NCALys(Z); c)NCA-Ser(tBu).

54

3.2

The layered micelle for micelle design 1.

55

3.3

NMR spectrum of PEG-poly(BLA) in DMSO.

56

3.4

The second polymer design for layered micelle.

58

3.5

NMR spectrum of PLA-poly(BLA) preparation in CDCl3 a)PLA-NHt
boc; b)PLA-OH(Z); c)PLA-poly(BLA).

59

3.6

NMR spectrum of poly(Lys)-PLA-poly(Lys) in DMSO.

61

3.7

Top: the pH of micelle solution on inner micelle size; Bottom: micelle
size variation based on salt concentration in water.

63

3.8

AFM image analysis of micelle size of micelle design 2. Left: 4x4
µm; Right: 1x1 µm

64

3.9

The second design of layered micelle.

64

xi

List of Schemes
Scheme

Page

2.1

Synthetic method of PLLA-PEI-PLLA triblock copolymer

26

3.1

Scheme of NCA monomer synthesis

53

3.2

Polypeptide polymerization scheme

57

3.3

O-N acyl migration of PLA-NH2

60

xii

Abbreviations
2-MeOx

2-methyl-2-oxazoline

3LM

Three-layered micelles

AFM

Atomic Force Microscope

BMA

n-butyl methacrylate

Boc2O

Di-tert-butyl decarbonate

BVqMAA

Polybutadiene-block-poly(1-methyl-2-vinyl pyridinium methyl
sulfate)-block-poly(methacrylic acid

CHCl3

Chloroform

DBU

1,8-Diazabicyclo(5.4.0)undec-7-ene

DCM

Dichloromethane

DDS

Drug Delivery System

DLS

Dynamic light scattering

DMAEMA

N, N-dimethylaminoethyl methacrylate

DMF

N, N-dimethylforaldehyde

DMSO

Dimethyl sulfoxide

DOX

Doxorubicin

EPR

Enhanced Permeability and Retention

GPC

Gel permeation chromatography

IPN

Inter-Penetrated Network

LCST

Lower critical solution temperature

NCA-BLA

N-carboxyanhydride--benzyl-L-aspartate

xiii

NCA-Lys(Z)

N-carboxyanhydride N--benzyloxycarbonyl-L-lysine

NCA-Ser(tBu)

N-carboxyanhydride O-tert-butyl-L-serine

NMR

Nuclear magnetic resonance

PAMAM

Poly(amidoamine)

PCL

Polycaprolactone

PDMAEMA

Poly(2-dimethylaminoethyl methacrylate)

PEG

Poly(ethylene glycol)

PEG-poly(Asp)

Poly(ethylene glycol)-polyaspartic acid

PEG-poly(Lys)

Poly(ethylene glycol)-polylysine

PEI

Polyethyleneimine

PGA

Polyglycolic acid

PGA–PEG–PGA

Poly(L-glutamic acid)–block-poly(ethylene glycol)–blockpoly(L-glutamic acid)

PIC

Polyion complex

PLA

Polylactic acid

PLA-poly(Asp)

Polylactide-poly(L-aspartic acid)

PLA-poly(BLA)

Polylactide-poly(-benzyl-L-aspartate)

PLGA

Poly(lactide-co-glycolide)

PLL–PEG–PLL

Poly(L-lysine)–block-poly(ethylene glycol)–block-poly(Llysine)

PMOx

Poly(2-methyl-2-oxazoline)

PNIPAm

Poly(N-isopropylacrylamide)

PEG

Poly(ethylene glycol)

xiv

PPG

Polypropyrene glycol

PTX

Paclitaxel

RAGE

Receptor for advanced glycation end product

ROP

Ring opening polymerization

SnOct2

Tin (II) 2-ethylhexanoate

TEM

Transmission electron microscopy

TFA

Trifluoroacetic acid

TFMSA

Trifluoromethanesulfonic acid

THF

Tetrahydrofuran

WAXS

Wide angle x-ray scattering

xv

CHAPTER 1
Introduction
1.1 Drug Delivery Systems
The advancement of drug design and discovery has improved the potency and
effectiveness of drugs for various challenging diseases. Despite that, drug delivery
methods need to be strategically planned in order to fully exploit the potential of new and
current drugs while minimizing the potential for metabolism or elimination. New drug
delivery systems (DDS) have been developed using “vehicles” to carry and deliver drugs
with more spatial and temporal control than traditional delivery systems via the direct
injection or simple diffusion of drugs.1,2 Desired characteristics of DDS are: 1)
biocompatible or biodegradable properties3,4, 2) minimized physiological foreign body
responses5,6, 3) enhanced drug loading7,8, and 4) a controlled drug release mechanism9-12.
To achieve those goal, research on DDS can focus on the design of vehicles composed of
selected macromolecules.
In general, complex biological systems exclude foreign objects in various ways.
For example, drugs that are delivered via an oral course often experience either
enzymatic or pH degradation, and conventional drug vehicles administered by systemic
injection tend to be cleared via spleenic and hepatic clearance pathways.13,14 In contrast,
DDS carriers with “stealth” capability which protect the drug and prolong bioactivity
during circulation have minimized physiological foreign body responses. Therefore, they
can avoid rapid clearance. For instance, poly(ethylene glycol) (PEG) is a successful
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example of a biocompatible polymer that achieves increased circulation time of
payloads.11,12
In order to enhance drug loading efficiency and desirable controlled release
system, the current focuses of polymeric DDS research are: design of the polymeric
nanostructures, physical and chemical conjugation of drugs, and addition of targeting
mechanisms.15,16
1.1.1 Drug delivery mechanisms
The route of administration of DDS can be broadly classified into 2 categories:
systemic delivery and local delivery. Systemic delivery has generally been applied to
treat diseases in the brain and internal organs such as the lungs, kidneys and the liver.17,18
Drug delivery vehicles are typically introduced via intravenous injection, intraperitoneal
injection, oral administration, and so forth.19,20 Contrary to the full body circulation of
drug carrier from systemic delivery, localized delivery such as injectable, implantable,
and transdermal systems allow a bulk fraction of drugs to be stored at a fixed
location.21,22 This type of drug delivery limits toxicity within the target area and greatly
increases the potency of therapeutic agents. Local drug delivery has been applied to
various targets including the brain and the skin.23-25
Drug delivery carrier are delivered to the target area by passive or active
mechanisms as illustrated in Figure 1.1.26 Passive targeting exploits the leaky vasculature
of tumor microenvironments to accumulate nanoparticles. For example, rapid cell growth
of abnormal epithelial cells results in poor packing and100 to 300 nm cavities between
cells (Figure 1.1A).26 Therefore, DDS smaller than 300 nm can access these areas and are
2

retained within the tumor microenvironment due to lack of lymphatic drainage.27 This
passive delivery process is called the enhanced permeability and retention (EPR) effect.2830

Figure1.1 Drug delivery system through passive and active systems.26

In contrast, active delivery vehicles incorporate target-responsive agents on the
surface of the nanoparticles. These types of DDS are capable of interacting with specific
receptors on the target cell as shown in Figure 1.1B. Ligands such as antibodies, folic
acid, and epidermal growth factor receptors have been used to promote tumor cell
uptake.31,32 For example, doxorubicin (DOX) is known as an effective cancer drug. Thus,
various DDS that utilize an active delivery mechanism have been designed to include
DOX for cancer treatments.33,34 Liu et. al. developed drug loaded nanoparticles prepared
from the block copolymer with a targeting oligopeptide, cRGD-polycarboxybetaine
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methacrylate-b-polybenzimidazole methacrylate.33 The resulting nanoparticles released
DOX at higher rate than the non-targeting system. In addition, this DDS contained a pH
sensitive benzimidazole moiety that released DOX at pH 5 and reduced toxicity to the
patient.33 pH-sensitive bonds have been used with targeting ligands to enhance targeting
capability.35 The extracellular matrix at wounded areas generate an acidic
microenvironment (pH 5 -6) that triggers cleavage of acid-labile linkages.36 Oh et al.
conjugated cell specific aptamers to PEG containing polymers by click chemistry.34
Then, DOX were attached onto these polymers via ester bonds. The subsequent
nanoparticles entered host cells via endocytosis, and the payload was released in the
cytoplasm either by enzymatic cleavage or acidic degradation of the ester bond.
1.1.2 Polymer-drug conjugates
One of the most studied approaches in DDS is to design polymer-drug conjugates.
By conjugating drugs with polymer carriers through covalent bonds, low-molecular
weight (MW) therapeutic agents are bound to DDS vehicles to increase drug efficacy
against specific diseases and prevent immune system recognition.37-39 In 1975, Ringsdorf
et al. investigated the potential use of polymer drug conjugates, and the idea has been
further developed by various groups.40-43
Figure 1.2 shows examples of common cleavable bonds used for polymer-drug
conjugates: imine, ester, disulfide, and hydrazone bonds. These connections are often
located at the ends of polymer chains or grafted at polymer side chains. For highly
branched polymers, drugs are connected to the peripheral branches. The conjugates are
usually stable throughout the circulation period. Payloads are usually released through
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disintegration of polymer backbone or cleavage of stimulus-responsive bonds under
desirable circumstances.

Figure 1.2 Typical stimuli-responsive functional groups.

Table 1.1 List of DDS studies using pH- and redox-sensitive drug release mechanisms

Linkage

Drug

Polymer

Release
mechanism

References

ester

Prednisolone

PEG

pH degradation

37

Saquinavir

PEG

pH degradation

44

Paclitaxel

PAMAM

pH degradation

41

Doxycyline

Poly(glu)

pH degradation

45

Paclitaxel

N-(2-hydroxypropyl)methacrylamide
N-(2-hydroxypropyl)methacrylamide
PEG

pH degradation

46

pH degradation

47

pH degradation

39

PEG-b-poly(glycerol
monomethacrylate)
PLA

pH degradation

48

PAMAM

pH degradation

50

Phe-Phe-Arg-methylketone

pH degradation

51

Camptothecin
Doxorubicin
Indomethacin

Cyclosporin A
7-Ethyl-10hydroxy
camptothecin
Paclitaxel

disulfide

49

salmon
calcitonin
Gd complex

PEG

Redox

38

P(OEGMA-co-GPMA)

Redox

52

Auristatin E

PEG

Redox

53

Docetaxel

mPEG-PBLG

Redox

54
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Table 1.1 Continued
Linkage

imine

hydrazone

amide

Drug

Polymer

Release
mechanism

References

DNA aptamer
AS1411

poly(2-((2(acryloyloxy)ethyl)disulfan
yl)ethyl 4-cyano-4(((propylthio)carbonothioyl)-thio)pentanoate-co-poly(ethylene
glycol) methacrylate)

Redox

55

Doxorubicin

PEG

pH degradation

39

Doxorubicin

mPEG-polycarbonate

pH degradation

56

Doxorubicin

PLA

pH degradation

43

Doxorubicin

HPMA

pH degradation

42

Dexamethasone

sodium heparin

pH degradation

57

.

Ciplatin

PEG-PLA

pH degradation

58

Adriamycin

PEG-poly(Asp)

pH degradation

59

Betulinic Acid

pH degradation

60

Vitamin E

N-(2-hydroxypropyl)methacrylamide
PEG-Poly(glu)

pH degradation

61

Doxycycline

poly(glu)

pH degradation

45

NPC1161

pH degradation

62

Daunomycin

N-(2-hydroxypropyl)methacrylamide
poly(Lys)

pH degradation

63

Doxorubicin

Pullulan

pH degradation

64

Platinate

N-(2-hydroxypropyl)methacrylamide
N- (2-hydroxypropyl)methacrylamide
PEG

pH degradation

65

pH degradation

66

pH degradation

67

Doxorubicin
RAGE-peptide

Appropriate literature describing drug release mechanisms with polymer-drug
conjugate designs is discussed in this section and summarized in Table 1.1. The ester
bonding is often used in polymer-drug conjugates because of its biodegradability and
ease of preparation. Dissociation of the ester linkage can be achieved by hydrolysis in an
acidic environment or an enzymatic degradation in an esterase abundant physiological
environment. Figure 1.3 (a) shows an example of DDS using an ester linkage between
6

paclitaxel (PTX) with generation 5 of poly(amidoamine) (PAMAM) dendrimer shown in
the blue sphere.41 This in vitro study showed that PTX was released through enzymatic
hydrolysis. Lv et. al. designed a drug release system using PEG-poly(lysine) where PTX
was conjugated to the side chain of poly(lysine) via ester linkages (Figure 1.3 (b)).68 This
polymer-drug conjugate delivered as a micelle form showed cytotoxicity toward tumor
cells.

b
)

Figure 1.3 a) Strategy to conjugate PTX onto polymer.41 b) PTX was conjugated onto a
linker on poly(Lys) side chain with ester bonds.68

Hydrazones and imines are the carbon-nitrogen double bonds made by reactions
between ketones or aldehydes and amines. Those functional groups are relatively stable
under physiological pH but readily degrade after internalization in the endosome at pH 56. As a prodrug, these linkages have been used to study release mechanisms of anticancer drugs such as DOX and PTX. Alani et al. designed the polymer-drug conjugate,
PEG-block-poly(aspartate-hydrazide) connected with PTX via a hydrazone by two
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different linkers, either levulinic acid or 4-acetyl benzoic acid (Figure 1.4).69 The
micelles formed by those polymer-drugs successfully showed cytotoxicity toward cancer
cell lines through hydrolysis. Etrych et al. prepared star shaped polymers comprised of
poly N-(2-hydroxypropyl) methacrylamide, and conjugated DOX onto polymers via
hydrazone linkage (Figure 1.5).42 The resulting polymer-drug micelles achieved
controlled release at pH 5 and cytotoxicity towards cancer cells.

Figure 1.4 PTX drugs were conjugated onto poly(Asp) though hydrazone conjugation.69

Unlike hydrazone and ester bonds, disulfides are cleaved via reduction to form
thiols. This linkage is uncommon for therapeutic drugs and polymer main chains.
Therefore, additional linkers containing a disulfide moiety such as 3,3’-dithiodipropionic
acid are used as a bridge between therapeutic agents and polymer backbones.68 In
addition, disulfides are also used as a bridging linker for polymer-protein conjugation
while maintaining the bioactivity of proteins.38,52 In summary, the polymer-drug
conjugation provides an innovative approach to stably store therapeutic agents inside
DDS as well as the ability to degrade and release the drugs in the desired locations.

8

Figure 1.5 Hydrazone conjugation of Dox on polymer chain.42
1.1.3 Micro- and nanoparticles
Colloidal carriers such as micro- and nanoparticles have been widely studied and
various designs of delivery particles have been tested for medical applications as
illustrate in Figure 1.6.70 These particles can encapsulate drugs in the interior of the
polymeric shell and protect the drug from exposure to the exterior environment.
Conventional drug release from polymeric particles utilizes two types of release
mechanisms: 1) diffusion, burst or bulk release, and 2) corrosive release.71 Diffusion
9

release of encapsulated drugs is achieved through the pores of polymeric nanoparticles
due to a concentration gradient (higher drug concentration in the particles, lower in the
biological microenvironment) until an equilibrium is reached. The burst/bulk release
mechanism is characterized by fast structural degradation.72 As water penetrates
nanoparticles, the physical and chemical structures experience different rate of
disintegration. Therefore, the nanoparticle loses its polymer backbone scaffold and the
cargo is released relatively fast in a short period of time. Contrary to burst release, the
corrosive model has slower structural degradation, and the drugs are released slowly as
the surface of the nanoparticles corrodes overtime.73 The release profile of some
micro/nanoparticles models have shown close to zero-order release, which is favored for
prolonged drug delivery.

Figure 1.6 Various design of drug delivery system
In general, the diameter of microparticles is greater than 1 m, which allows to
store relatively large amounts of therapeutic agents. Size variations can be achieved
through different particle preparation techniques such as oil-in-water (o/w) and water-inoil-in-water (w/o/w) emulsions.74 Microparticles are limited by their sizes with respect to
10

uptake into cells other than phagocytic cells.73 Although microparticles show poor
systemic delivery due to aggregation and clotting, they serve as a viable and effective
candidate for local delivery, such as subcutaneous injection with sustained release
systems.75,76
In contrast to microspheres, nanoscale particles are readily able to penetrate
cancer cell barriers and access the areas of interest without compromising the integrity of
the particle structure.28,77 A high surface area to mass ratio of nanoparticles provides the
possibility to conjugate greater amount of specific targeting ligands, leading efficient
drug delivery to the target sites.78
1.1.4 Ion complexes
Poly-ionic complex (PIC) vehicles are prepared by exploiting the electrostatic
interactions between opposite charges between anionic and cationic block copolymers, or
cationic block copolymers and polyanionic therapeutic agent such as DNA.79 The
stability of PIC can be tuned by charge density, concentration, pH, and ionic strength and
molecular weight of ionic segments.80-82 The binding capacity of PIC for drug cargo
increases as the molecular weight of the polyelectrolyte increases.83 The polymer
concentration also affects the stability of PIC.84,85 For instance, as PIC solution
concentrations increase, aggregation of PIC results in high polydispersity and
inconsistent nanoparticle sizes due to nucleation.86 Additional variables, including pH
influences the binding of therapeutic agents to PIC, as charge is pH dependent.81 The pH
is also a stimulus to release payload from the PIC. Furthermore, the stability of PIC can
be influenced by solution ionic strength.82 Moderate amounts of ions facilitate the
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formation of PIC, but solutions with strong ionic strength will inhibit the nucleation and
further destabilize PIC.84,87 A complex that incorporates genetic material is specifically
called polyplex.88 Polycations can bind, condense, protect and release DNA, which is
then efficiently taken up by cells.88 Cationic poly(amino acid)s such as poly(Lys) are
suitable candidate PIC building blocks because payload release is facilitated by
protonated poly(amino acid)s. Polyethylenimine (PEI) and polyamidoamine are both
polycations capable of efficiently condensing the gene for the gene therapy, however,
cytotoxicity of such polymers are main challenges.89-91 The new design of polymeric
vectors form block copolymers between PEI and PEG, and PEG shields the ionic
complex from the exterior environment and the DNA condensation has been successfully
achieved.83
1.1.5 Complex copolymer micelles
In general, polymeric micelles are nano-scale particles that are composed of
amphiphilic block or graft copolymers.92 The core-shell structure is attributed to the selfassembly of the polymer chains and solvent affinity toward each polymer segment.
Polymeric micelles typically range in size from 10 nm to 200 nm, and this range allows it
to penetrate through the epithelial membrane packing.92 Critical micelle concentration
indicates the stability of polymeric micelles in a diluted environment.93 The lower the
value, the more stable the micelles are. There are several driving forces for stabilize
polymeric micelles. In aqueous media, the hydrophilic polymer segment forms the shell
of the micelle; whereas the hydrophobic polymer segment forms the inner core of the
micelle and hydrophobic drugs are stored inside the micelle core. Therefore, a
hydrophobic interaction is one of the driving forces for micelle formation and it is
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achievable through increasing the hydrophobic block of the micelle, using a crosslinking
agent at the core of the micelle, or utilizing polymer-drug interactions to reinforce the
hydrophobicity of the core.94
Regarding the targeted controlled release, a pH-responsive mechanism is one of
common mechanisms to discharge payloads.95 After endocytosis, micelles experience a
low pH 5-6 condition within the cellular the endosome or a mild acidic condition with the
solid tumor and inflammatory tissue microenvironments.96,97 Micelles that consist of
polyester or acid-labile moieties discharge therapeutic agents in a programmed manner
under these conditions.
Polymers are further designed to prepare DDS micelles with specific
morphomogies. Groschel et al. created multicompartment micelles with various
compositions of diblock or triblock copolymers in various solvent systems to induce
morphology changes.98 In this study, the shape of nanoparticles changed from a regular
corona micelle to hamburger shape, worm-like shape, and lamella morphology.98 The
morphology changed as the energy repulsion effect between two blocks within polymers
and the repulsion force were tuned by the selection of solvents to achieve a kinetic
manipulation. 99 Wang et. al proposed the morphology manipulation of
multicompartment micelles via computational simulation among sphere, cylinder, and
vesicle by adjusting the block length of two binary block copolymer systems.95
Synatschke et al. designed a multicompartment micelle with polybutadiene-block-poly(1methyl-2-vinyl pyridinium methyl sulfate)-block-poly(methacrylic acid)(BVqMAA)
triblock copolymers as a drug delivery vehicle and fluorescene probe.100 The resulting
micelle was further covered by PEG-poly(lysine) and successfully delivered model drugs
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to target sites. In addition to these studies, more researchers have focused on morphology
change by composition of block length in the copolymers and polymer sizes of multiple
copolymers.101 Furthermore, these complex polymer micelles composed of those multiple
copolymers will be able to effectively respond to various stimulus such as body
temperature, pH, nanoparticle surface charge, magnetic field, light, and targeting ligands.
1.1.6 Hydrogels
Hydrogels are a class of drug delivery matrix, and its composition is similar to
that of living tissues; thus, it is used for tissue engineering and localized treatment.102-104
Hydrogels are composed of porous polymeric networks and comprises over 80% water
through hydrogen bonding within the networking material. Hydrophilic therapeutic
agents can be embedded within the array of polymer chain networks in three-dimensional
space. Controlled drug release mechanisms can be achieved through enzymatic,
hydrolytic, or stimuli-responsive degradation.105 Despite hydrogel’s great attributes on
DDS, major hurdles, such as the mechanical weakness of the material and lack of
hydrophobic drug storage are challenges that need to be overcome.
Hydrogels can be formed through chemical or physical approaches. Chemical
approaches generate covalent bonds among polymer chains. One of common methods is
ultraviolet (UV)-initiated radical crosslinking. PEG-dimethacrylate and -diacrylate are
commonly used photo-radical crosslinkers.106,107 Other crosslinking agents, such as
genipin, glutaraldehyde and formaldehyde are often used to crosslink end groups or side
chains of polymers using mild reaction conditions. These permanent covalent bonds

14

substantially alter elasticity, crystallinity, water solubility, and mechanical strength of the
resulting hydrogel.108-110
Physical crosslinking approaches are driven by a variety of forces such as
hydrophobic, electrostatic, hydrogen bonding, stereocomplexation, and pi-pi interactions.
Physical entanglement of polymer chains is induced upon specific stimulus response
(e.g., temperature, light, pH, or solvent) and alters the hydrogel properties mentioned
above. 110-112 The absence of potential toxic crosslinking agents does give physical
crosslinking advantages over the chemical crosslinking methods. Some physically
crosslinked hydrogels are reversible if the driving force is temporarily applied.113
However, the irreversible gelation mechanism can be exploited to introduce the solution
in a non-invasive manner and form the hydrogel in situ at the target area.114
In general, sustained drug release from hydrogels is dictated by diffusion. A high
concentration of the drug is stored either in a reservoir or within the hydrogel network,
and it slowly diffuses out of the polymeric network. The drug release rate is constant and
time dependent. However, the controlled drug release can be achieved if hydrogel
degradation rate was precisely tuned. Degradation of the hydrogel network results in
enlarged porous sizes or increased mesh sizes. The drug diffusion rate significantly
increases as mesh size increases.115 Common degradation methods are hydrolysis,
enzymatic degradation, and physical deformations.116,117 Hydrogels that contain ester
linkages disintegrate through hydrolysis overtime, and thus promote controlled drug
release at low pH conditions. Copolymers containing biodegradable PLA or PCL are
often utilized for hydrogel preparation.118 For the physical degradation of hydrogels,
specialized inorganic nanoparticles can be incorporated in the network. For example, by
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applying external force such as a magnetic field or ultrasound, the encapsulated
nanoparticles physically deform the hydrogel network to increase the mesh size and
release therapeutic agents into the target area.117,119,120.
Micelles made of PEG-PLA block copolymers are one of the most studied
systems for drug delivery.121-124 Fujiwara et al. utilized this polymer system for the
injectable thermos-responsive hydrogel with newly developed mechanism in 2001.114 By
mixing two micelle solutions composed of stereoisomeric poly(L-lactide)-PEG-poly(Llactide), (PLLA-PEG-PLLA) and poly(D-lactide)-PEG-poly(D-lactide), (PDLA-PEGPDLA), the micelles underwent chain exchanges, and the resulting stereocomplexation
formed the core of micelles. With elevated temperature, the chain exchange rate
increased and that induced crosslinking among the micellar cores. Consequently, a
hydrogel was formed due to non-equivalent chain exchange rates. The properly tuned
micelle solution produced an injectable hydrogel system for drug delivery when gelation
occurred at physiological temperature.114 In 2012 Abebe et al. developed the secondgeneration hydrogel, which significantly increased the mechanical strength of the
material by adjusting the micelle components with polymers of different MWs.123
Recently, the enhanced micelle was modified into the layered micelle for gene
therapy.60,62,125
1.2 Scope and Outline of the Dissertation
The scope of this dissertation is associated with polymeric micelles and networks
which are inspired by the recent advances of polymeric drug delivery systems. Two
different types of ionic polymer systems were used to establish micelle-hydrogel drug
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delivery systems. For the first system, we developed thermo-responsive hydrogels from
multilayered micelles containing DNA. In the other system we explored the potential of
multilayered micelles by ionic poly(amino acid)s for potential dual drug delivery.
Chapter 2 focuses on the hydrogel system prepared from DNA-loaded threelayered micelles (3LM) composed of block copolymers, namely, PLA-PEG-PLA/PLAPEI-PLA, comprised of a PIC core (DNA/PEI), a PLA intermediate layer, and a PEG
outer layer. The 3LM solutions were successfully prepared into hydrogels with tunable
properties by precise control of conditions including temperature, concentration, and
polymer length and compositions. The hydrogels were analyzed for their structure,
stability, mechanical strength, sol-to-gel transition mechanism, and degradation behavior.
In vitro studies of DNA-loaded hydrogels were further discussed for gene delivery
capability. Biodegradable, biocompatible, and efficient gene vectors with tunable
properties were achieved.
Chapter 3 focuses on polyelectrolyte micelle systems. Poly(amino acid)s have
gradually gained attention as a functional polymer backbone for drug delivery. They are
biocompatible and possess a variety of driving forces to self-assemble into nanoparticles
which makes them versatile biomaterials. Forces like hydrogen bonding, and
hydrophobic and electrostatic interactions were explored for drug delivery vehicle design.
This chapter reports several attempts at making functional multilayered micelles using
combinations of block copolymers consisting poly(aspartic acid), poly(lysine), PEG,
PLA, and other poly(amino acid)s. The resulting micelles were characterized and
evaluated for their drug delivery capability.
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Chapter 2
Characterization and Optimization of PLA Stereocomplexed Hydrogels for Local
Gene Delivery Systems
2.1. Introduction
Localized gene therapy approaches have found increasing popularity in the fields
of tissue engineering, immune therapy, localized disease therapy, long term depots for
drugs, and localized site production “factories” for proteins.126-128 For localized therapies,
hydrogels have been utilized as coating materials for implants, intravascular stents, thin
films (membrane), porous scaffolds, and in-situ forming hydrogel depots. Traditionally,
hydrogels are produced outside of the body (after incorporating genetic material), and
then implanted into the body. The disadvantage of such approach is that the matrix must
be implanted through surgical means. Recently, the development of injectable hydrogels,
which undergoes solution to gel transformation in the body has attracted considerable
attention. Some of the advantages of these injectable delivery systems include minimal
invasiveness and surgery related complication, and the materials can be molded to fit
specific shapes and crevices.129,130 In particular, temperature responsive hydrogels are
highly desirable systems because the well-regulated physiological temperature is the only
stimulus needed for sol-to-gel transition.
The encapsulation and delivery of plasmid DNA and siRNA have been reported
using physically crosslinkable injectable hydrogels derived from natural polymers such as
alginate, fibrin and gelatin.131-137 The slow degradation properties and uncontrolled
release profiles for these hydrogels have promoted researchers to develop block
copolymer based injectable hydrogels. Some of the commonly utilized physically
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crosslinkable copolymers include the bioresorbable hydrophilic and hydrophobic blocks
such as polyethylene glycol (PEG), polylactides (PLA), poly(lactide-co-glycolide)
(PLGA), and polypropyrene glycol (PPG); for example, PLA-PEG-PLA, PLGA-PEGPLGA, and Pluronic® .138-140 To improve their low mechanical strength typically
associated with physical crosslinking, the chemically crosslinkable systems have been
often used. Reactive functional groups such as fumarate, methacrylate, and acrylates are
typically conjugated to gelling block copolymer or hydrophilic homopolymer systems
(PEG is a commonly utilized hydrophilic homopolymer).141-145 Although chemical
functionalization yields robust hydrogels, there are serious safety and biocompatibility
concerns. The reactive cross-linkable groups and their degradation byproducts are known
to cause localized toxicity and necrosis.146 For the hydrogel systems incorporate the
genetic material (pDNA, siRNA, etc.) in their naked form, the mechanism for loading of
the genetic material relies simply on physical entrapment during the sol-to-gel transition
process. These systems typically show low therapeutic efficiency due to lack of ability to
retain the gene inside and prevent rapid and uncontrolled diffusion. Moreover, the
released genetic material has low in-vivo half-life due to degradation by nucleases and
inability to successfully cross the cell membrane.147 To overcome these drawbacks,
researchers have used cationic blocks such as polyethyleneimine (PEI) and poly(2dimethylaminoethyl methacrylate) (PDMAEMA) to condense DNA into a polyplex
particle and entrap it within the hydrogel matrix.148-152 The main hurdle in the
development of injectable hydrogels for the localized gene therapy is the fine balance
needed between high mechanical strength and biocompatibility. Crystallization of
polymer chains is an attractive alternative to a relatively toxic chemical crosslinking in
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the production of an injectable hydrogel with biologically relevant mechanical
strength.123 In particular, the stereocomplex crystal is produced through physical
association of enantiomeric blocks of a thermo-gelling system (crosslinking junction).
This crystal has relatively high thermal/physical stability, which allows it to act as a
semi-permanent crosslinker similar to that produced by chemical methods.153
In our previous work, the combination of triblock copolymers, PLLA-PEI-PLLA and
PLLA-PEG-PLLA, has shown to produce nano-sized three-layered micelles (3LM),
where the DNA/PEI polyplex is localized within a hydrophobic capsule.125 The 3LM
with relatively less toxic low MW linear-PEI has incorporated high concentrations of
DNA. Additionally, 3LM proved to possess high stability in neutral pH, while its
encapsulated payload was released through a pH mediated trigger allowing for controlled
release properties. We further reported the initial studies of the thermo-gelling system
between the DNA-loaded 3LM and the stereoisomeric block copolymer, PDLA-PEGPDLA.154 Overall, these systems have shown a great potential as non-viral gene delivery
vectors. In this paper, we focus on relationships of the 3LM compositions and their
hydrogel properties to understand the role of PLA stereocomplexation in the system. The
sol-to-gel transition behavior as a function of block MW and polymer composition in
3LM is studied. Additionally, to precisely tune the PLA stereocomplex derived
hydrogels, the chemical and physical mechanisms of gel forming and degradation
processes are investigated.
2.2. Materials and Methods
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2.2.1. Materials
The monomers, L-lactide and D-lactide with the trademarked names of PURASORB
L and PURASORB D, respectively, were purchased from Purac Biochem (Netherlands).
PEG with a number-average molecular weight (Mn) of 2000 and 3350 Da, the monomer
2-methyl-2-oxazoline (2-MeOx) 98%, trans-1,4-dibromo-2-butene (99%), tin (II) 2ethylhexanoate (SnOct2), di-tert-butyl dicarbonate (ReagentPlus, 99%), trifluoroacetic
acid (TFA), Salmon sperm DNA, chlorobenzene (extra dry), methanol (extra dry),
acetonitrile (anhydrous, > 99.8%), and toluene (extra dry) were purchased from Sigma
Aldrich (St. Louis, MO). Regenerated cellulose dialysis tube with MWCO (3.5-5k) was
purchased from Spectrum Labs (Rancho Dominquez, CA). The purification and storage
procedures for all monomers, catalyst, macroinitiators and solvents used in this study can
be found in our previous reports.123,125
2.2.2. Measurements
Nuclear magnetic resonance (NMR) spectroscopy was used to determine the
chemical structures and calculate the number-average molecular weight (Mn) for all block
copolymers. 1H NMR was performed on a Varian 500 MHz instrument at room
temperature with CDCl3 and DMSO-d6 as solvents. Solid-state 13C NMR experiment of
lyophilized hydrogel samples was performed through CP/MAS method on JEOL-ECZ 400
MHz spectrometer with a 13C operating frequency of 100 MHz and a spin rate of 10 kHz.
The number- and weight-average molecular weights (Mn, Mw) and polydispersity of block
copolymers was determined by gel permeation chromatography (GPC) on a Shimadzu LC20AD with two Jordi DVB 500 Å (250 x 10 mm) columns calibrated with polystyrene
standards at 35 °C, and THF was used as the mobile phase with a flow rate of 1.0 mL/min.
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The hydrodynamic diameter of micelles was determined by a dynamic light scattering
(DLS) technique on a Malvern Zetasizer Nano ZS90 at concentrations of 0.01, 0.1 and 1%
at room temperature in triplicate. Mechanical properties of the resulting hydrogels were
characterized on a TA AR 550 rheometer using a cone-and-plate geometry with a 4° cone
angle, 40 mm diameter plate, and 61 mm Gap. Rheological measurements were conducted
as a frequency sweep from 0.01 to 40 Hz at 37 °C. Crystal structure was analyzed by wide
angle x-ray scattering (WAXS) on a Bruker AXS D8 advance X-ray diffractometer for
flashed freeze / lyophilized powder samples.
2.2.3. Synthesis of triblock copolymers
The facile and controlled synthesis of the ionic triblock copolymers PLLA-PEIPLLA (MW: 1700-2000-1700) using an amine protection/de-protection approach can be
found in our previous report.125 Briefly, the PEI precursor α,ω-dihydroxy poly(2-methyl-2oxazoline) (PMOx) was prepared by the ring opening polymerization (ROP) of 2-methyl-2oxazoline (2-MeOx) using the bifunctional initiator trans-1,4-dibromo-2-butene. Linear
PEI was obtained through base hydrolysis of the amide functional groups of PMOx. The
secondary amines of PEI were then fully reacted with excess di-tert-butyl dicarbonate to
obtain N-Boc protected PEI (PEI-N-Boc). The hydroxyl end-capped homobifunctional PEIN-Boc, was used as a macroinitiator for the living ROP of L-lactide using the organometallic catalyst Sn(Oct)2 to yield the triblock copolymer PLLA-(PEI-N-Boc)-PLLA. The
N-Boc protecting groups were then deprotected using TFA to yield the desired ionic
triblock copolymer PLLA-PEI-PLLA. The amphiphilic triblock copolymers, PLLA-PEGPLLA and PDLA-PEG-PDLA were prepared by the ROP method, using the macroinitiator
PEG-diol and the monomers L-lactide and D-lactide, respectively. The complete synthesis
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procedure for the preparation of the amphiphilic triblock copolymers can be found in our
previous report.123
2.2. 4. DNA loaded 3LM micelle preparation
The detailed method for the formation of unique 3-layered micelle (3LM) system with
the ability to entrap high MW DNA using a dual encapsulation approach was reported
previously.125 Briefly, the preparation of the DNA loaded 3LM is divided into two
consecutive steps. Step 1, encapsulation via organo-micelle: the ionic triblock copolymer
PLLA-PEI-PLLA (inner polymer) was dissolved in 1 mL DMSO and equilibrated at room
temperature. Bulk DNA (1 mg) in 200 µL of pure water was gradually added to the
polymer/DMSO solution under vigorous stirring. The solution was allowed to equilibrate at
room temperature for 1 h under gentle stirring and was diluted with 4 mL of THF. The
solution was dialyzed against THF using dialysis tubes (MWCO of 3.5-5 kD) to obtain the
DNA loaded organo-micelles. Step 2, aqueous stabilization via an amphiphilic layer: To
the organo-micelle/THF solution, the amphiphilic triblock copolymer, PLLA-PEG-PLLA
(outer polymer, MW: 800-2000-800), was added to obtain a homogenous transparent
solution. The mixed solution was then added dropwise to a 10 mL pure H2O under
vigorous stirring. The solution was placed under a gentle stream of compressed air to firstly
evaporate the organic solvent THF, followed by concentrating the aqueous solution to the
desired volume to obtain the targeted concentration of the 3LM solution. To study and
optimize the properties, 3LM with different inner:outer polymer weight ratios were
prepared.
PDLA-PEG-PDLA flower type micelle (D-micelle) was also prepared to use for
stereocomplexed hydrogel formation. PDLA-PEG-PDLA (MW: 800-2000-800) in THF
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(20-40 w/v%) was added dropwise in DI water under vigorous stirring. THF and excess
water were evaporated to obtain predetermined concentration of D-micelle solutions.
Alternatively, the asymmetric PDLA-PEG-PDLA micelles with mixture of long/short PEG
blocks (D-micelle-(%)S) were prepared.123 The long-PEG copolymer, PDLA-PEG-PDLA
(MW: 800-3350-800) and the short-PEG copolymer, PDLA-PEG-PDLA (MW: 800-2000800) were weighed with the ratio of 100:0, 70:30, 50:50, 30:70, and 0:100 (%). Each
mixture was fabricated into micelle form by same method above.
2.2.5. Stereocomplexed hydrogel preparation
The hydrogel formation procedure is similar to that reported for the standard PLAPEG-PLA associative micelle network 123 and 3LM-hydrogel network 154,155 utilizing the
PLA stereocomplexation. Controlled hydrogel formation was achieved by blending 3LM
and counter-gelling PDLA-PEG-PDLA micelle solutions. The separately-prepared micelle
solutions with matched concentration (for example, both solutions can be 20 wt% to obtain
20 wt% hydrogel) were mixed at adjusted volumes which were calculated in order to
contain 1:1 ratio of PLLA-PEG-PLLA in 3LM and PDLA-PEG-PDLA in D-micelle with
ultrasonic wave applied at 4°C in a scintillation vial. The mixture was allowed to sonicate
at 4°C for 30 minutes or until a homogeneous solution is obtained. The vial is then
transferred to a temperature-controlled circulating water bath and the temperature of the
bath is gradually increased with 1 h hold at each temperature interval. The vial tilting
method was used to determine sol to gel transition behavior, if the mixture flowed then it
was reported as a solution and if it did not flow for at least 8 seconds it was reported as a
gel.149,156.

24

2.2.6. Hydrogel degradation
In vitro degradation study was conducted to simulate the degradation in
physiological environment. The inner:outer polymer ratio within 3LM was set to 1:10, and
the concentrations of 3LM and D-micelle-S were set to 20wt%, as optimal setting based on
the result from earlier experiments. After the hydrogel was formed, 200 mg each of the
hydrogel was placed into 16 vials. Seven of those vials contained the hydrogel, 1 mL of
100 mM sodium acetate buffer with pH 4.5, and 1 mg of proteinase K. The next seven vials
contained hydrogel, 1 mL of 10 mM Tris HCl with pH 7.4, and 1 mg of proteinase K. The
fourteen vials were then placed in an incubator at 37C. The last two vials of hydrogel were
dried with nitrogen gas, weighed, and then analyzed to determine the water content in the
original hydrogel. Each vial for both pH buffer solutions was removed from the incubator
at 3 h, 10 h, 1 day, 3 days, 7 days, and 14 days for the degradation analysis. The
supernatant in each vial was decanted into a different vial, lyophilized, weighed, and then
analyzed. Three different sets of this degradation test were performed.
2.3. Results and Discussion
2.3. 1. Synthesis of block copolymers
The triblock copolymers PLLA-PEI-PLLA, PLLA-PEG-PLLA, PDLA-PEGPDLA and P(DL)LA-PEG-P(DL)LA were prepared as previously reported.125 Although
the controllable ring-opening polymerization (ROP) of cyclic lactide monomers readily
produced well defined triblock copolymers, only synthesis of PLLA-PEI-PLLA required
a multi-step route to yield the comparative quality of copolymer. In general, the synthesis
of PEI/PLA block copolymers has considerable difficulties such as incompatible
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solubility of PEI with that of lactide or PLA, aggressive nucleophilic nature of PEI
amines, and low reactivity of PLA/PEI macromolecular coupling reactions. By utilizing
the amine-protection chemistry, we were able to develop a facile and well-controllable
synthetic procedure to yield well-defined block copolymers (Scheme 2.1). The PEI-NBoc intermediate is soluble in a range of organic solvents and the potential initiation
sights of the secondary amines are protected leaving only the terminal hydroxyl groups
for ROP to occur. The final triblock copolymer of PLA-PEI-PLA was obtained by the
mild deprotection of Boc groups using 50 wt% TFA/CHCl3 solution for 5 min. The
deprotection step leads to protonation of the PEI block rendering a positive charge which
is necessary for the complexation step with negatively charged DNA.

Scheme 2.1. Synthetic method of PLLA-PEI-PLLA triblock copolymer
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2.3.2. 3LM and hydrogel formation
Formation of DNA-loaded 3LM was previously confirmed by transmission electron
microscopy (TEM) in our report, where the stained DNA was observed in the core and
surrounded by polymeric shells with micelle diameters 100-200 nm.125 The compositions
of 3LM and proposed structure of its stereocomplexed hydrogel are illustrated in Figure
2.1. The chain-exchange mechanism between enantiomeric PLLA-PEG-PLLA and
PDLA-PEG-PDLA micelle solutions were previously reported.123 To further study the
mechanisms and optimize the properties of 3LM-hydrogels, 3LM with different
inner:outer polymer ratios were prepared as shown in Table 2.1. Additionally, Table 1
lists the different PEG block length of PDLA-PEG-PDLA used for D-micelles. 3LM and
D-micelles were prepared with various concentrations to examine the gel formation
process.

inner
PLLA-PEI-PLLA
outer

+
polyplex/PLLA/PEG

PLLA-PEG-PLLA

PDLA-PEG-PDLA

3LM

L-micelle
sc

sc

Stereocomplexed Hydrogel

D-micelle

Figure 2.1. Schematic representation of 3LM and hydrogel components.

2.3.3. Effect of formulation on micelle size and composition
was determined by DLS measurements. The hydrodynamic radius is given for the
3LM solutions from four inner:outer ratios investigated, 1:1, 1:5, 1:10 and 1:20 (Figure
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2.2a). The “inner” value corresponds to the weight fraction of PLLA-PEI-PLLA, whereas
the “outer” value corresponds to that of PLLA-PEG-PLLA which makes up the corona of
3LM. As agreed with the previous reported 3LM data, the 1:1 ratio formulation gave the
particles with monodispersed sizes of 100-200 nm. However, with increasing outer ratio
values in the 3LM formation process, a second peak at <50 nm was observed. The
intensity of the second peak increased with increasing outer ratio, while the intensity of
the original peak decreased. The second peak at sizes <50 nm corresponds to the simple
flower-micelles composed of simple PLLA-PEG-PLLA triblock copolymers (L-micelle);
and the hydrodynamic sizes observed are comparable to the micelles from triblock
copolymers with same molecular weight.157 Therefore, with increasing inner:outer ratios,
the micellar solution is populated with two sets of micelle particles, 3LM (containing
DNA) and the flower micelles (DNA free). The DLS data indicates the size of 3LM is not
significantly affected by the increasing concentration of the PLLA-PEG-PLLA outer
layer. Even though the excess of PLLA-PEG-PLLA outer polymers has a negligible
effect on the 3LM self-assembly properties, the presence of L-micelles may affect the
sol-to-gel transition behavior and gel properties considerably and that will be discussed
below. We have also examined the 3LM size using the longer PLLA block of the outer
polymer, PLLA-PEG-PLLA (1200-2000-1200) (Figure 2.2b). Interestingly, the thickness
of hydrophobic intermediate layer created by both inner and outer PLLA blocks did not
affect to the overall diameter of 3LMs.
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Table 2.1. Composition ratios of inner:outer polymers in 3LM and mixed PEG
block sizes in D-micelles.
Micelle ID

3LM-1/1
3LM-1/5
3LM-1/10b
3LM-1/20
3LM-1/1-1200
D-micelle-Sc
D-micelle-70S
D-micelle-50S
D-micelle-30S
D-micelle-0S

3LM composition I/O polymer weight ratio (%)a
D-micelle polymer weight ratio (%)
Inner polymer
Outer polymer
short-PEG
long-PEG
PLLA-PEI-PLLA PLLA-PEG-PLLA PLLA-PEG-PLLA PDLA-PEG-PDLA PDLA-PEG-PDLA
(1700-2000-1700) (800-2000-800) (1200-2000-1200)
(800-2000-800)
(800-3350-800)
50
50
17
83
9
91
5
95
50
50
100
0
70
30
50
50
30
70
0
100

a:

Unless specified, the N/P ratio was kept as 12 by adjusting amount of DNA and PLLAPEI-PLLA.
b:
Unless specified, 3LM used for most of hydrogel evaluations was 3LM-1/10.
c:
Unless specified, D-micelle used for most of hydrogel evaluations was D-micelle-S.
The effect of the inner:outer polymer ratios on the 3LM particle size and structure

a)

b)
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Figure 2.2. DLS intensity analysis of: (a) 3LM compositions prepared by different
weight ratios of PLLA-PEI-PLLA (inner layer) and PLLA-PEG-PLLA (outer
layer); (b) 3LM sizes at inner;outer ratio 1:1, but different PLLA block length of
outer block copolymers.
2.3.4. Gelation mechanism and sol-to-gel phase transition
Thermo-responsive hydrogels were prepared using the stereocomplexation
mechanism of enantiomeric polylactides. Stereocomplexed (physically crosslinked)
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hydrogels are attractive because they are free from potentially toxic cross-linkers
typically required for chemically crosslinked hydrogels. Although the mechanical
strength of physically crosslinked hydrogels are generally lower than chemically
crosslinked hydrogels, the enantiomeric mixture of PLA-PEG-PLA micelles has shown
significantly increased storage modulus of stereocomplexed hydrogels by controlling the
polymer sizes and micelle packing parameters.123 The hydrogel formation is driven by the
stereocomplexation of the PLLA and PDLA blocks of the micellar solution, which is the
result of the chain exchange between neighboring micelles. The inter-micelle chain
exchange predominates at higher temperatures and concentrations, leading to an
irreversible hydrogel.
The insight of hydrogel formation from 3LMs was studied in this work. As
depicted in Figure 2.1 above, the PDLA block is supplied by the blank D-micelles as one
of the sources of stereocomplexation in the hydrogel formulations. Whereas, there are
several sources the PLLA block can be obtained in the system. The intermediate
hydrophobic layer of 3LM is composed of two sets of PLLA, one derived from the DNA
complexed PLLA-PEI-PLLA copolymer and the second from the corona forming PLLAPEG-PLLA copolymer. The stereocomplexation ability of each PLLA segment was
investigated by replacing the corona forming copolymer (outer polymer) with the racemic
and amorphous PDLLA-PEG-PDLLA which has no ability to form stereocomplex
crystals during the 3LM-hydrogel preparation step. The presence/absence of the
stereocomplexation diffraction peaks was determined through WAXS after lyophilized
the mixtures of 3LM and D-micelle solutions. The 3LM containing PDLLA-PEGPDLLA outer layer did not form a hydrogel after mixing with D-micelle solution at all
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temperatures and concentrations investigated. Justifying this result, we observed no
stereocomplexation diffraction peak in the WAXS spectra for this mixture (Figure 2.3a)
compared to the typical stereocomplex peaks observed in simple micelle mixture of
PLLA-PEG-PLLA and PDLA-PEG-PDLA (Figure 2.3c). In contrast, the stereocomplex
diffraction peaks at 2θ = 12 and 21° were clearly observed in the WAXS spectra of the
hydrogel forming 3LM including semicrystalline PLLA-PEG-PLLA outer layer mixed
with D-micelles (Figure 2.3b). Therefore, the PLLA blocks of the outer layer polymer are
responsible for stereocomplexation event leading to hydrogel formation. For 3LM with
increasing inner:outer ratios, 1:5, 1:10, 1:15 and 1:20, the stereocomplexation event is
likely a combination of chain exchange between both 3LM and excess of blank PLLAPEG-PLLA micelles and blank PDLA-PEG-PDLA micelles, leading to hydrogel
formation.
a)

b)

c)

Figure 2.3. WAXD profiles of hydrogels prepared mixing the following micelles
with PDLA-PEG-PDLA micelles: (a) 3LM using PDLLA-PEG-PDLLA (racemic
polymer) outer layer; (b) typical 3LM from PLLA-PEG-PLLA outer layer; and
(c) simple PLLA-PEG-PLLA micelles.
The phase transition (sol-to-gel) diagrams for the different formulations are shown in
Figure 2.4. The phase diagram of 3LM with the 1:1 inner:outer ratio mixed with D31

micelle (Figure 2.4a) shows a linear decrease in the sol-gel transition temperature with
increasing polymer concentration. Hydrogels with clinically relevant sol-gel transition
temperatures, 37 °C and 25 °C can be obtained at 20 wt% and 25 wt% respectively. The
phase diagram of the different inner:outer formulation in 3LM is shown in Figure 4b.
The concentration of all the solutions was kept constant at 20 wt% and thus only the
effect of the increasing population of excess PLLA-PEG-PLLA micelles was
investigated. The phase diagram shows a linear decrease in sol-gel temperature with
increasing inner:outer ratio, indicating the incorporation of blank L-micelle contributes
with the overall network formation (crosslinking). The 3LM-1/20 solution has the highest
L-micelle population, and the sol-to-gel transition occurred at the lowest temperature that
is comparable to the 3LM-blank mixture (50/50% L- and D-micelles). The chain
exchange rate of PLA blocks between all micelles depends on the polymer and micelle
compositions. The faster exchanges between simple L- and D-micelles for the systems
with larger inner:outer ratios in 3LM would make the network structure even at the low
temperature. Furthermore, the relatively large size of 3LM may not be suitable for the
close micelle packing needed for robust hydrogel formation. The blank PLLA-PEGPLLA micelles could be able to bridge the gap and allow for more crosslinking points. As
a result, the hydrogels are readily formed at lower temperatures compared to the system
without blank PLLA-PEG-PLLA micelle (i.e. 1:1 inner:outer). Overall, sol-to-gel
transition temperature is precisely tunable with micelle concentration and composition
(Figure 2.5).
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Figure 2.4. Sol-to-Gel phase diagram: variation of: (a) total polymer
concentrations with constant 3LM inner:outer = 1/1; and (b) 3LM composition of
inner:outer ratios with constant polymer concentration at 20 wt% (open square:
solution state, closed triangle: gel state by tilt method).

Figure 2.5. Summary of so-to-gel phase diagram.
2.3.5. Mechanical strength
The mechanical strength of hydrogels is an important physicochemical property,
which plays a crucial role in the utilization of the hydrogel for biomedical applications.
The mechanical strength of the DNA loaded 3LM was characterized using rheological
profiles. Figure 6 shows the storage (G’) and loss (G”) moduli of the 3LM hydrogels at
inner:outer ratios of 1:1 and 1:10, and the control hydrogel from the simple PLLA-PEGPLLA micelle; plotted immediately after mixing with the PDLA-PEG-PDLA micelle
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solution. All measurements were performed at 37 °C with a constant solution
concentration of 20 wt%. The L+D blank micelles show the highest storage modulus,
indicating that the presence of 3LM in the hydrogel network leads to a decrease in
mechanical strength. The hydrodynamic sizes of the co-gelling 3LM and PDLA-PEGPDLA micelles are considerably different. Thus, the inter-micelle distance, micelle
packing density, micelle aggregation behaviors and chain exchange kinetics would be
different than the L+D blank micelles. In our previous study, we utilized time-resolved
small angle neutron scattering (TR-SANS) to investigate the effects of chain exchange
kinetics on the formation of L+D stereocomplexed hydrogels.157 Model dependent
analysis of the scattering data suggested, (1) micelle volume increased due to increase in
aggregation number following non-equilibrium chain exchange, (2) chain exchange rate
was influenced by the size of the PEG corona, with larger PEG corona showing a delayed
response in aggregation number increase and (3) micelles initially formed small and tight
clusters, which then grew to larger clusters and eventually formed the hydrogel network.
The storage modulus is considerably lower for the inner:outer ratio 1:1 formulation than
the control in Figure 2.6. When the simple PLLA-PEG-PLLA micelles are incorporated
into the gelling solution by increasing the inner:outer ratio, a clear increase in G’ is
observed. The improvement in mechanical strength of the 1:10 inner:outer formulation
can be attributed to increase in micelle packing density. The simple PLLA-PEG-PLLA
micelles increase the crosslinking points, effectively bridging the gap that existed
between 3LM and PDLA-PEG-PDLA micellar populations in the 1:1 inner:outer
formulation.
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Figure 2.6. Rheological properties with (a) time and (b) frequency plots for the
stereocomplex hydrogels prepared using 3LM with different inner:outer polymer
ratios and the PLLA-PEG-PLLA micelle.
2.3.6. Effect of PEG block length on the hydrogels
We have previously studied the effect of PEG block length in PLA-PEG-PLA to the
kinetics of gelation process and hydrogel properties.123 Compared to the control hydrogel
prepared from PLLA-PEG-PLLA (MW: 800-2000-800) and PDLA-PEG-PDLA (MW:
800-2000-800) simple micelle solutions, mixing the different copolymers with longer
PEG block yielded different sol-to-gel transition temperatures and mechanical strength.
The inter-micelle exchange of PLA chains for the micelles with short PEG polymer were
found to be more rapid than those with long PEG polymer. The micelles made of the
mixed PEG size copolymers (as illustrated in Figure 2.7) exchange PLA blocks with
different rate and the sol-to-gel transition temperature changed linearly by the mixing
ratios.123 Moreover, the hydrogels from the short/long mixed PEG micelles exhibited
remarkably higher modulus.123

D-micelle-S D-micelle-50S

Figure 2.7. Schematic illustration of D-micelles with mixed PEG block length.
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Table 2.2. Comparison of so-to-gel transition and stability of 10 wt%
stereocomplexed hydrogels using D-micelles with mixed PEG length (inner:outer
of 3LM kept 1/5)
3LM (inner / outer)
PLLA-PEI-PLLA a /
PLLA-PEG-PLLA b

D-micelle
PDLA-PEG-PDLA
(800-2000-800) /
(800-3350-800)

sol-to-gel
transition
temperature
(°C)

D-micelle
45
D-micelle-70S d
50
3LM-1/5
D-micelle-50S
60
D-micelle-30S
70
D-micelle-100S
65
a
block molecular weight: 1700-2000-1700 (Da)
b
block molecular weight: 800-2000-800 (Da)
c
after increased to 80°C for all samples
d
D-micelle ID, 70S means short-/long-PEG polymer ratio 70/30 wt%

time before
starting to flow c
(min)

1
10
> 60
> 60
3

In this study we mixed long-PEG copolymer, PDLA-PEG-PDLA (MW: 800-3350800) to prepare D-micelles (Figure 2.7) and used for 3LM-hydrogel formation. Table 2.2
summarizes the observation of sol-to-gel transition temperatures and flow behavior of
3LM-hydrogels by tilt method. In agreement with our previous work, the PEG length
affected to the gel formation and properties of 3LM-hydrogel system. The transition
temperature is the highest when using D-micelle-30S (short-/long-PEG = 30:70 wt%),
that also indicates the slower chain exchange of longer polymers. However, those gels
with long/short mixed length micelles (50S and 30S) do not flow over 60 min and are
apparently more robust than the hydrogel with D-micelle from PDLA-PEG-PDLA (8002000-800) only.

2.3.7. Hydrogel degradation study
The progress of hydrogel degradation was monitored periodically by the weight loss
of hydrogels in both neutral and acidic environment with addition of the enzyme.
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Proteinase K is known to selectively degrade PLLA with relatively low crystallinity. As
shown in Figure 2.8, the hydrogel in the Tri-HCl buffer at pH 7.4 maintained a fairly
consistent weight up to 2 weeks with 83% in average of the original weight. In contrast,
the hydrogel in the acetate buffer at pH 4.5 showed a steady decline and 48% in average
of the initial weight remained as a gel after 2 weeks. It should be noted that the hydrogels
physically disintegrated after 2 weeks of period, and no reliable trend on the degradation
profile was obtained. Separately, enzyme free degradation samples exhibited relatively
slower rate.

Figure 2.8. Weight loss of 3LM-hydrogels in pH 7.4 and pH 4.5 at 37°C in the
presence of proteinase K.
To study the degradation process of 3LM-hydrogel, the supernatants of the hydrogel
test solutions after separation and lyophilization were analyzed by GPC and NMR. As the
GPC curves of the accurately re-dissolved samples in Figure 2.9 show, the PEG (MW =
2000, polydispersity = 1.08) peak was detected after 24 h incubation in both neutral and
acidic conditions with the presence of the enzyme. Therefore, it was speculated that some
degree of PEG blocks was initially cleaved and released into the solution within one day
regardless of the pH by enzymatic degradation at the junction with the PLLA blocks.
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However, the released components at neutral condition remained unchanged whereas the
degradation in an acidic solution progressed in time (Figure 2.9b); the PEG peak
appeared immediately, followed by the smaller molecular weight oligomers from PLLA
block were released. Additionally, the higher molecular weight polymers were released
into the buffer after 1 week. Those polymers, identified as PLLA-PEG-PLLA and PDLAPEG-PDLA, are believed to be diffused into the solution as a result of the disintegration
of the micelle-hydrogel matrix. Based on these results, the degradation process and
mechanism of the 3LM-hydrogels are proposed as follows: 1) the enzyme, proteinase K
hydrolyzed the PLLA chain at the PLLA-PEG junction (the outer most PLLA of the
micelle core) and released some PEG blocks into the solution, 2) further enzymatic
degradation of PLLA proceeded slowly within 3LM, and 3) physical disintegration of
hydrogel resulted in the release of remaining block copolymers. Furthermore, acidic
hydrolysis of PLLA chain in pH 4.5 played a significant role to promote the degradation
process.
The supernatants of hydrogel degradation samples were also analyzed by 1H NMR.
The NMR spectra in Figure 2.10 show a PEG peak at 3.47 ppm and multiple peaks
corresponding to CH3 and CH for PLLA and its degradation products such as lactic acid
and oligomers in the buffer solutions at different pH after 1 and 7 days. The intensity of
all spectra was normalized using internal reference peak. It revealed that the
concentration of degraded PLLA products was significantly higher in the acidic solution
(red) than in the neutral solution (green) after 1 week. For the supernatants after 1 day
(blue) and 7 day (red) in the acidic solution, the PEG peak was detected since day 1, and
the PEG peak (see the enlarged spectra) and degraded PLLA species increased
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significantly after 1 week. These data correlate to the GPC results and support the
proposed degradation mechanism. In the neutral pH solution, there was no noticeable
difference of degradation products of PLLA, such as lactic acid and oligomers, between 1
day (data not shown) and 1 week (green). Based on those results, it is hypothesized that
the DNA can be released from the hydrogel faster in the acidic solution, and degradation
of PLLA block, i.e., intermediate layer of 3LM.

a)

b)

p H7 .4
1
5
3
1

25

we e k
day
day
day

26

27
28
29
Elu t io n t im e ( m in )

PEG
(MW=2000)

p H4 .5

PEG
(MW=2000)

1
5
3
1

30

31

25

we e k
day
day
day

Copolymers
(MW=3k-5k)

26

27
28
29
Elu t io n t im e ( m in )

Oligomers
(MW=100-600)

30

31

Figure 2.9. GPC profiles of the supernatants at (a) pH 7.4 and (b) pH 4.5, after
lyophilized and re-dissolved in THF.

2.3.8. Hydrogel analysis by solid-state NMR
To further investigate the PLA crystal structures in the hydrogel from L-/D-micelles,
CP/MAS 13C NMR spectra were obtained for the polymer and lyophilized hydrogel
samples at different stages. Figure 2.11 shows the spectra of PLLA-PEG-PLLA (8002000-800) and stereocomplexed hydrogels (mixture of L- and D-micelles) which was
immediately lyophilized, slowly air-dried, and treated in buffer at pH 7 and pH 4.5 for 5
day. The advantage of CP/MAS NMR is to identify the different polymer packing state.
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The spectrum of PLLA-PEG-PLLA (a) shows PLLA-methyl peak around 20 ppm,
PLLA-methine peak around 72 ppm, PEG peak at 74 ppm, and PLLA-carbonyl peak
around 175 ppm. Most of PLLA carbons display as multiple peaks due to the
semicrystalline nature. For example, the inserted spectra are the expansion of carbonyl
peak region in which amorphous and crystal carbon peaks are distinctly separated.153 The
freshly made and lyophilized hydrogel from enantiomeric micelles of PLLA-PEG-PLLA
(800-2000-800) and PDLA-PEG-PDLA (800-2000-800) (b) showed all three forms for
the carbonyl carbon; homocrystal, amorphous, and stereocomplex crystal at 173, 174.5,
and 176 ppm, respectively. This indicates that relatively low degree of chain exchange
and stereocomplex formation still leads transformation of the micelle solution into a gel
form. When the hydrogel was slowly dried up in air (c), we observed only distinguished
peak of stereocomplexed PLA for carbonyl carbon. The hydrogels remained in buffer
solutions after 5 days maintained good structure of stereocomplex PLA (d, e) although
PEG and small PLA oligomers already started to release into the buffer solutions. Since
both hydrolysis and biodegradation of PLA start from amorphous region, it is reasonable
that stereocomplexed PLA remains longer in the hydrogel. Note that the small peaks at
30 and 184 ppm are attributed to the acetate buffer used for degradation test.
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Figure 2.10. 1H NMR spectra of the lyophilized supernatants from the samples:
pH 4.5, after 1day (blue), pH 4.5, after 7 day (red), and pH 7.4, after 7days (green).
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Figure 2.11. Solid-state 13C NMR spectra of (a) the PLLA-PEG-PLLA polymer,
and hydrogels from L- and D-micelles with (b) rapid and (c) slow dehydration
process, and hydrogels after 5 days degradation tests at (d) pH 7 and (e) pH 4.5.
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2.3.9. Gene delivery prospectives of 3LM-hydrogels
Table 2.3. List of biological evaluations previously reported for 3LM and
stereocomplexed hydrogels.
Sample

Evaluation
Loading efficiency 125
Micelle stability 125
DNA release 125
Cell toxicity 125

3LM

RAW 264.7 Uptake 154

GFP expression in RAW
264.7 154
GFP expression in primary
spleen macrophages 154
DNA release 154
3LMhydrogel Macrophage uptake 154

Method
Heparin extraction
SYBR Gold Assay
Dextran Sulfate
competition assay
MTT Assay
FA-modified 3LM
with YOYO-1
labeled DNA
Flow cytometry
Flow cytometry

SYBR Gold Assay
Flow cytometry

Results
>50%
No DNA exclusion
No release at pH 7.4
Rapid release at pH 4.5
Higher IC50 than PEIpolyplex
Highly specific uptake
in activated
macrophages
High uptake in
activated cells
Significantly higher
expression in activated
cells
No release at pH 7.4
Slow release at pH 4.5
High uptake from pH
4.5 supernatant

As mentioned in Introduction, 3LM as a DNA delivery carrier has been evaluated in
the previous paper125, and its stereocomplexed hydrogel has also shown the potentials in
our preliminary study (summarized in Table 3).154 However, physical properties,
structural transformation, and polymer compositions of the stereocomplexed hydrogel
would significantly affect biological test results. The relationship between the micelle
structures and gelation mechanism, gel strength, and degradation process revealed in this
detailed and systematic study demonstrated the reproducibility and potential use of 3LMhydrogels for optimized local gene delivery systems.
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2.4. Conclusions
PLA stereocomplexed hydrogel systems incorporating DNA-loaded 3LM were
obtained and analyzed. The sol-to-gel transitions of the 3LM-hydrogels were observed to
vary based on several factors of formulation conditions. The hydrogel systems with a solto-gel transition at the desired temperature were obtained by optimizing the polymer
concentration in the system and weight ratio of inner:outer polymers (PLLA-PEI-PLLA /
PLLA-PEG-PLLA) during the 3LM formation. Furthermore, the mechanical strength of
the hydrogels improved through the use of PDLA-PEG-PDLA micelles with mixed PEG
block length. The structure, properties, and mechanistic aspect of the 3LM-hydrogel
system were well correlated with stereocomplexation behavior of enantiomeric PLA
blocks. The degradation study revealed that the 3LM-hydrogel degraded fairly quickly in
an acidic environment and remained stable in a neutral environment. The PEG blocks
started to be released through enzymatic degradation at the junction of the block
copolymer regardless of the pH, and subsequent PLLA degradation proceeded in the
acidic solution. These results show the 3LM-hydrogel is a well-structured and tunable
injectable non-viral gene vector that is readily prepared through stereocomplexation
between enantiomeric PLLA/PDLA thermo-gelling systems.
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Chapter 3
Multilayered Micelles Containing Poly(Aspartic acid) and Poly(Lysine) for Drug
Delivery
3.1. Introduction
Nano- and micro-scale drug delivery vehicles have been widely used to deliver
anticancer agents and drugs for the following reasons; 1) it is capable of drug delivery in
less invasive control, 2) the materials can be biocompatible and/or biodegradable so that
less harmful effect to patients, 3) the nanoparticles are able to travel within the blood
stream for certain period for effective drug delivery,158 4) smart properties can be added
on the vehicles to release drugs responding to a variety of stimuli,159 and 5) the efficacy
of drugs is significantly increased.160
Polymeric micelles are the most studied drug delivery vehicles composed of coreshell type structures. For example, the micelles prepared from an amphiphilic block
copolymer, poly(ethylene glycol)-block-poly(lactide) (PEG-b-PLA) have been studied
and used for 3 decades. Relatively hydrophobic drugs can be encapsulated into the PLA
core during the micelle formation. PEG, a biocompatible polymer, forms a shell of the
micelle and increases a circulating period of coated nanoparticles.158,161 However, passive
drug loading into micelles causes inefficient and uncontrollable loading rates.162
Furthermore, the encapsulation of drugs is limited to hydrophobic examples.162
Alternatively, micelles made of copolymers with multiple (three or more) blocks
or the multiple types of block copolymers are capable of incorporating drugs in specific
parts of resulting micelles via different mechanisms. In this case, each block has its own
unique solvent affinity and chemical responses. By adjusting polymer affinities towards
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solvent, the morphology of the micelles or nanoparticles experience different level of
morphologies, from worm-like to sphere morphology.98 As described in Chapter 2, our
group recently reported a new design for a three-layered micelle (3LMs). In this construct
two diblock copolymers were used: PLA-PEG-PLA and PLA-polyethylenimine-PLA
(PLA-PEI-PLA).125,163 The micelle design successfully used low toxicity, short and linear
cationic PEI to condense large DNA into an organo-micelle. PEG-PLA was used as a
coating to encapsulate the organo- micelle in aqueous medium to afford a 3LM. Thus, the
3LM contained a PEG corona layer, a PLA intermediate layer, and a PEI-DNA complex
in the core. This work, led by Daniel Abebe, demonstrated new class of micelle, which
featured encapsulation of hydrophilic or ionic therapeutic agents with stabilization of the
micelle core by inter-layer shielding.125
Harada et al. explored polypeptides to form PIC using the pairs of opposite
charges to study a PIC theory.79 The micelle was prepared using two diblock polymers:
PEG-polyaspartic acid (PEG-poly(Asp)), and PEG-polylysine (PEG-poly(Lys)). These
polymers formed PIC when the pair polypeptides have the equal molecular charges.79
Cisplatin was able to be loaded into and stored in a PEG-poly(Asp) micelle with release
under physiological condition.164 Ryu et al. prepared a pH sensitive drug delivery vehicle
composed of PEI-poly(Lys)-polyglutamic acid triblock copolymer for gene therapy.165
The micelle size and zeta-potential both showed dependency upon pH changes. The
cytotoxicity of the polycomplex was relatively small and transfection efficiency was
improved by 1.5 and 2.5 times compared to PEI only at low pH. Nguyen et al. designed
polyion complex (PIC) micelles using polystyrene-graft-poly(2-vinylpyridine) and
poly(acrylic acid)-block-poly(2-hydroxyethyl acrylate) polymers where poly(2-
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vinylpyridine) as a cationic block and polyacrylate as an anionic block in the complex.166
The resulting micelle showed no toxicity and smooth cell uptake.166 In addition, the size
of the micelle could be tuned based on the pH of the micelle solution.166 All polyionic
micelles mentioned above are examples of the potential drug delivery vehicles.
We are interested in combined technologies of (1) complex micelle encapsulation
and (2) versatile chemical conjugation of drugs. As one of the most attractive polymers to
enable both physical and chemical modifications, poly(amino acid)s have been widely
studied.167-169 For chemical conjugation, the side functional groups of poly(amino acid)s
include, but are not limited to, hydroxyl, amino, and carboxylic acids moieties that allow
for example, imine, ester, and acetal linkages to drugs. These linkages are acid labile and
subject to nucleophilic attack under physiological conditions for drug release. Hence, the
project in this chapter revolves around designing a hierarchical micelle using poly(amino
acid)s to formulate the DDS structure.
The choices of amino acid monomers in this specific work were lysine and aspartic
acid which were shown to be both biocompatible and biodegradable. Both polymers are
ionized at neutral pH. Cationic polymer, poly(Lys), and anionic polymer, poly(Asp),
form PIC through electrostatic interactions. The charge balance between two polyionic
chains has been shown to strongly influence the stability of complexes.170,171 In addition,
the -helix secondary structure that forms between poly(Lys) and PEG via hydrogen
bonding provides additional stability to the overall micellar structure.170 Additionally,
pH responsive dissociation would provide prolong circulation.36 In this report, 2 different
PIC micelle designs incorporating poly(amino acid)s, PLA, and PEG will be discussed.
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•

Micelle design 1: Micelles from linear triblock copolymers systems composed of
PEG, ionic, and hydrophobic blocks

•

Micelle design 2: Micelles from two diblock copolymers with cationic or anionic
block in each copolymer and preparation of flower micelle system

The research also attempted to achieve drug conjugation, drug release, and structure
reinforcement for multicompartment micelle by utilizing the versatility of poly(amino
acid).
3.2. Experimental
3.2.1. Material
Both mPEG-NH2 and H2N-PEG-NH2 were purchased from LaysanBio and were
lyophilized prior to polymerization. For monomers, L-aspartic acid -benzyl ester, N6carbobenzyloxy-L-lysine, O-tert-butyl-L-serine, and 1,8-diazabicyclo(5.4.0)undec-7-ene
(DBU) were purchased from Sigma Aldrich. L-lactide and D-lactide were purchased
from Purac Biochem (Gorinchem, The Netherlands) and were recrystallized from toluene
before use. Trifluoroacetic acid (TFA) was purchased from Oakwood Chemical, and
trifluoromethanesulfonic acid (TFMSA) and thioanisole were purchased from Sigma
Aldrich. For solvents, heptane was purchased from Sigma Aldrich, and hexane,
tetrahydrofuran (THF), acetone, diethyl ether, dichloromethane (DCM), and dimethyl
sulfoxide (DMSO) were purchased from Fisher Scientific. Hexane, tetrahydrofuran, and
N,N-dimethylforaldehyde (DMF) were distilled before use. Regenerated cellulose dialysis
tubing with a molecular weight cut-off (MWCO) of (3.5–5k) was purchased from
Spectrum Labs.
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3.2.2. N-carboxyanhydride (NCA) synthesis
3.2.2.1. Synthesis of N-carboxyanhydride -benzyl-L-aspartate (NCA-BLA)
NCA synthesis was first reported by Hermann Leuchs.172 Later, the FuchsFarthing method, phosgene based NCA synthesis, was developed and then widely
adapted for NCA synthesis.172-174 Briefly, 20 mL of anhydrous THF was added to 2 g of
L-aspartic acid--benzyl ester under an inert gas environment. Separately, 2.6 g of
triphosgene was dissolved in THF and added into the reaction flask during reflux. The
reaction was complete when all solutes dissolved after 30 min. The volume of the
reaction solvent was reduced to half after the reaction was completed, and hexane was
added and the mixture was stored in a freezer overnight for further recrystallization. The
product was recrystallized and filtered twice with a 94% overall yield. The final pure
product was stored in glove box for later use.
3.2.2.2. Synthesis of N-carboxyanhydride N--benzyloxycarbonyl-L-lysine (NCALys(Z))
To a flask, 20 mL of anhydrous THF was added to 2 g of N-carbobenzyloxy-Llysine under an inert gas environment. Separately, 2.6 g of triphosgene was dissolved in
THF and added into the reaction flask during reflux. The reaction was complete when all
solutes had dissolved after 30 min. The volume of the reaction solvent was reduced to
half after the reaction was completed, and hexane was added to and the mixture was
stored in a freezer overnight. The product was recrystallized and filtered twice with 60%
overall yield. The final product was stored in glove box for later use.
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3.2.2.3 Synthesis of N-carboxyanhydride O-tert-butyl-L-serine (NCA-Ser(tBu))
To a flask, 20 mL of anhydrous THF was added to 2 g of O-tert-butyl-L-serine
under an inert gas environment. Separately, 2.6 g of triphosgene was dissolved in THF
and added to the reaction flask during reflux. The reaction was complete when all solutes
had dissolved after 30 min. The volume of reaction solvent was reduced to half after the
reaction was complete, and hexane was added and the mixture was stored in a freezer
overnight. The product was recrystallized and filtered twice with 75% overall yield. The
final product was stored in glove box for later use.
3.2.3. Polymer synthesis
3.2.3.1. poly(Lys(Z))-PEG-poly(Lys(Z))
Lyophilized amine-terminated bifunctional PEG was dissolved in DMF and
NCA-Lys(Z) was also dissolved in DMF in a separate flask. The reaction flask was
prepared under an inert environment. Initiator (PEG) solution was ten added to the NCA
monomer solution. The reaction was carried out at room temperature for 2 days. The
resulting polymer was subsequently precipitated using diethyl ether and the polymer
product was obtained after filtration.
3.2.3.2. poly(Lys)-PEG-poly(Lys)
Dried poly(Lys)-PEG-poly(Lys(Z)) 0.5 g was dissolved in 5 mL of trifluoroacetic
acid. A volume of 1 mL of 33% hydrogen bromide in acetic acid was added to the
polymer solution. The deprotection process was completed in 30 mins. The resulting
polymer was then precipitated in diethyl ether, filtered, and stored in freezer for later
experiments.
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3.2.3.3. PLA-NH2
Ethanolamine was dissolved in chloroform (CHCl3), and an equal molar amount
of di-tert-butyl dicarbonate was added to the solution to complete N-Boc protection. The
protected initiator was then purified by column chromatography with CHCl3 and
methanol. Lactide and dry, purified 0.1 g N-Boc protected ethanolamine was dissolved in
5 mL anhydrous DCM. One equivalent of one to one ratio of DBU/DCM solution to
initiator was added to the reaction mixture. The solution was stirred at room temperature
for 1 h. DBU was neutralized by introducing a slight excess of benzoic acid to the
solution. The product, PLA-N-Boc was reprecipitated using isopropanol. The final
product was then filtered and dried in a vacuum oven at room temperature for 2 days. For
deprotection of the amine end group, 500 mg PLA-N-Boc was dissolved in 12 ml of
DCM /TFA(1:1 vol) was added. After 15 min, the reaction solvent was completely
removed at reduced pressure. The final product, PLA-NH2 was redissolved in DCM and
5M NaHCO3 was used to the neutralize amine. Solvent was removed at reduced pressure,
and the mixture of PLA-NH2 and PLA-OH was dried before the next step. It was noted
that the rearrangement reaction occurred during the workup process, and PLA-NH2 was
the minor product (vide infra).
3.2.3.4. PLA-poly(-benzyl-L-aspartate) (PLA-poly(BLA))
Dried PLA-NH2 and NCA-BLA were dissolved in DMF in two different flasks
under an inert environment. Initiator solution was then added into the NCA monomer
solution dropwise. The reaction was carried out at 40 °C for 24 h and the resulting
polymer was reprecipitated in cold methanol. The white solid was filtered and dried
under vacuum.
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3.2.3.5. PLA-poly(L-aspartic acid)(PLA-poly(Asp))
PLA-poly(BLA) was dissolved in TFA, and 1M TFMSA/thioanisole was then
added to the reaction flask. The mixture was stirred at 0 °C for 30 min. The mixture was
precipitated with cold diethyl ether. The white solid product, PLA-poly(Asp) was filtered
and dried under vacuum.
3.2.4. Nanoparticle preparation
3.2.4.1 Nanoparticle prepared by an emulsion method
PLA (5 mg) was dissolved in 0.5 mL of CHCl3. The mixture was then added to 1
mL of a 0.5% w/v PLA-poly(Asp) aqueous solution with vigorously stirring and
subsequent vigorous sonication in an ice bath. After solvent was evaporated.
Subsequently, 1 mL of 0.5% w/v poly(Lys)-PEG-poly(Lys) aqueous solution was added
into emulsion solution under vigorous stirring.
3.2.4.2 Drug encapsulation efficiency
A model drug was introduced into the polymer solution in organic solvent during
the emulsion preparation in order to encapsulate it into the resulting polymeric particles.
One mg of prednisone or nabumetone was dissolved along with PLA in CHCl3. Then,
micelles or emulsions were prepared as descripted above.
3.2.5. Instrumentation
The chemical structures were characterized by proton nuclear magnetic resonance
(1H NMR) for all polymers using JOEL 400 MHz and Varian 500 MHz instruments at
room temperature. The NMR solvents used were CDCl3 and DMSO-d6. The
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hydrodynamic diameter of micelles was examined by dynamic light scattering (DLS)
with a Malvern Zetasizer Nano ZS90 at a concentration of 0.1%(w/v) at room
temperature in triplicate. Zeta potentials were also characterized with ZS90 using a
dipping cell. Microscopic imaging of micelles was achieved by atomic force microscopy
(AFM) using from AFMWorkshop TT-AFM with silicon probe with resonance between
160-225 kHz on mica surface.
3.3. Result and Discussion
3.3.1. NCA monomer synthesis
The cyclic monomers, NCA-BLA, NCA-Lys(Z), and NCA-Ser(tBu) were
synthesized from triphosgene and the corresponding protected amino acids. Scheme 3.1
shows the synthetic scheme of the side-group protected NCA monomers. The starting
material was insoluble in THF upon addition of triphosgene. The reactions were complete
when all solutes had dissolved. Due to the reactivity of anhydrides, resulting monomers
were susceptible to nucleophilic attack from water. Multiple filtrations and
recrystallizations were required to remove the potential acid byproduct, triphosgene, and
small quantities of self-polymerized compounds.173,175 The purified monomer, NCA-BLA
was able to be stored in a glovebox under an inert atmosphere for up to 2 weeks,
however, self-polymerization was noted overtime. Thus, NCA monomers required
careful preparation and storage.
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Scheme 3.1 scheme of NCA monomer synthesis
NCA-Lys(Z) was synthesized in a similar manner, however, the purification
process required a more demanding approach. 1H NMR characterization revealed that
some degree of NCA-Lys(Z) monomer converted to the oligomer after filtration and
recrystallization. Figure 3.1 shows the NMR spectra of NCA monomers. The spectrum of
NCA-Lys(Z) (b) shows the methine peak, k, broaden at 4.3 ppm, which indicates the selfpolymerization of monomers. The shoulder peaks next to the benzene aromatic peaks, m,
also are clear indication of the presence of polymer within the NCA monomer. Once
oligomers formed, further purification provided no significant improvement on the purity
of the product regardless the choice of solvents. Moreover, during the drying process,
small portions of NCA-Lys(Z) would show ring-opening overtime. Thus, the final
monomer product contained portions of the lysine homopolymer.
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Figure 3.1 NMR spectrum of NCA monomer in DMSO a)NCA-BLA; b)NCA-Lys(Z);
c)NCA-Ser(tBu)
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3.3.2. Micelle design-1

Figure 3.2 The layered micelle for micelle design 1
Triblock copolymer systems were designed with a PEG block, an ionic block, and
a branched hydrophobic block to form a corona, an intermediate layer, and a core in a
multilayered micelle respectively. Poly(Asp) was used as an intermediate anionic block
as its acid side chain could serve as a site for drug conjugation. The hydrophobic PLA
block was introduced as a graft onto the polymer main chain or form multi-arm
architecture as shown in Figure 3.2. One of the target copolymers was PEG-poly(Asp)poly(Ser). PLA blocks were planned to graft onto the hydroxyl side groups of poly(Ser)
as shown in Scheme 3.2A. Using a commercially available PEG-NH2 as a macroinitiator,
the intermediate block was prepared by ring-opening polymerization (ROP) of NCABLA in DMF. The third segment poly(Ser(tBu)) was extended by adding NCA-Ser(tBu)
monomers into the same reaction vessel. However, the resulting length of poly(Ser(tBu))
was much shorter than the theoretical; the growth of the polymer was appeared to be
terminated at the early stage of the reaction by 1H NMR monitoring. Past research
suggested that this result might be attributed to a termination by the side reactions.176 For
the polymerization in DMF at room temperature, two non-living polymers were
observed; N-formyl polypeptide and carboxylic acid terminated polypeptide.176
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An alternate design of the triblock copolymer system was to have branched PLA
blocks. Instead of extending the polymer with a poly(Ser) segment, the amino endgroup
of PEG-poly(BLA) was reacted with glycidol to yield multiple hydroxyl groups which
could initiate PLA polymerization. However, the outcome was not favored, and the
branch was not formed. The cause of this result may be due to the termination of the end
group of PEG-poly(BLA), thus the growth of the chain was limited. Despite these issues,
PEG-poly(BLA), as shown in Figure 3.3, was successfully prepared, and the project was
modified using two diblock copolymers to construct the micelle structure. The methine
peak c of poly(BLA) segment shifted in the 1H NMR to 4.68 ppm from 4.61 ppm of its
monomer, NCA-BLA (as shown in Figure 3.1). Similarly, peak f shifted to 8.17 ppm
from 8.98 ppm as indicative of ring opening of the cyclic monomer. However, multiple
small peaks observed near the amide proton suggested poly(BLA) segments with various
molecular weights were presented.

Figure 3.3 NMR spectrum of PEG-poly(BLA) in DMSO
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Scheme 3.2 Polypeptide polymerization scheme
3.3.3. Micelle design-2
Two types of diblock copolymers were synthesized to form PIC multilayered
micelles as illustrated in Figure 3.4.
3.3.3.1. PLA-poly(Asp) Synthesis
PLA-poly(Asp) synthetic route is shown in Scheme 3.2B. At first, PLA-NH2, the
macroinitiator for the NCA-BLA polymerization was attempted. The process started with
the protection of ethanolamine on the amine side with di-tert-butyl dicarbonate (Boc2O).
The N-Boc protection reaction was selective and relatively fast with quantitative
conversion due to the strong nucleophilicity of amine. Polymerization of lactide, a cyclic
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lactate dimer, required careful preparation: drying the initiator was critical and the
reaction condition also affected significantly to the product. The conventional method for
lactide polymerization is a bulk synthesis from lactide with organometallic catalyst,
Sn(Oct)2. However, the N-Boc protected PLA terminal was susceptible to the cleavage of
the carbamate bond and it caused polymerization in both directions of ethanol amine at
high temperatures or in the presence of Lewis acid.177 Thus, a base catalyzed
polymerization was considered to be a safe approach. DBU, a non-nucleophilic organic
base was used to catalyze ROP of the lactide which proceeded faster than the Sn(Oct)2
catalyzed process. After the reaction, DBU was neutralized with benzoic acid to form a
DBU complex, and it was dissolved in alcohol for purification. However, high
polydispersity caused by rapid polymerization was one of the major drawbacks for the
DBU catalyzed synthesis.

Figure 3.4 The second polymer design for layered micelle
Deprotection of N-Boc group was achieved in acidic conditions in a relatively
short time around 15 min, and the subsequent product, PLA-NH2, was purified by
extraction to remove TFA salts. According to the 1H NMR spectrum shown in Figure
3.5a, the result showed two triplets at 4.2 ppm, which are methylene protons adjacent to
the ester, and 2.9 ppm represented the amine terminal methylene protons, and the other
sets of triplets at 3.4 ppm and 3.7 ppm represented rearranged PLA (Figure 3.5b). These
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Figure 3.5 NMR spectrum of PLA-poly(BLA) preparation in CDCl3 a)PLA-NH-tboc;
b)PLA-OH(Z); c)PLA-poly(BLA)
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results indicated that the free primary amine stemmed from the ethylene chain can access
the closest carbonyl carbon of the PLA backbone and form a five-membered ring
intermediate as shown in Scheme 3.3. The possibility of five-membered ring intermediate
promoted the unwanted rearrangement of amine end group.178,179 This “backbiting” the
fast nucleophilic amine attack resulted in the alcohol terminated PLA. The use of a longer
hydrocarbon chain would likely prevent the rearrangement since the favorable fivemembered ring would not result.

Scheme 3.3 O-N acyl migration of PLA-NH2
Although PLA-OH was the majority of the product instead of PLA-NH2, the
crude polymer intermediate was used to prepare PLA-poly(Asp) as a macroinitiator.
Anhydrous DMF dissolved both NCA monomers and macroinitiators, and the solution
was stirred at room temperature for one day. After the reaction, the mixture was purified
by precipitating into methanol and ether. From the 1H NMR spectrum in Figure 3.5c, no
monomer peak was observed after polymerization. Analysis of the integration ratios
between linking ethylene proton, f, and total methine protons from repeating poly(BLA),
c, showed the target polymer with desire size with 10 repeating units was achieved.
However, seemly diblock copolymer could be two homopolymers or one diblock
copolymer with limited polypeptide repeating units, and either scenario had similar
responses in precipitating solvent and average integration value on NMR. Diblock
copolymers were then deprotected by TFA-TFMSA-thioanisole reagent combination.180
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The polymer was fully dissolved in the mixed solution and the reaction was stirred for 15
min at room temperature. The resulting polymer was precipitated in ether. Multiple
precipitations were not able to fully remove contaminating reagent from the polymer. The
purity of the product was able to be improved via dialysis.
3.3.3.2. PEG-poly(Lys) and poly(Lys)-PEG-poly(Lys) synthesis
Poly(Lys)-PEG-poly(Lys) was prepared separately to form the second polymer
for the outer layer of the micelle design (Scheme 3.2C). PEG-NH2 was lyophilized prior
to polymerization. NCA-Lys(Z) was prepared with the method mentioned above Section
3.2.2.2. The 1H NMR spectrum in Figure 3.6 indicated poly(Lys)-PEG-poly(Lys)
copolymer. However, this product would be a mixture with the homopolymer poly(Lyz) :
existed, which was generated from the monomer purification process as the result of selfpolymerization. The polymer was then deprotected with 33% HBr/ acetic acid solution to
remove the benzyl group on the lysine side chain. The PEG-poly(Lys) diblock copolymer
was prepared in similar approach.

Figure 3.6 NMR spectrum of poly(Lys)-PLA-poly(Lys) in DMSO
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3.3.3.3. Micelle formation
For the micelle formation, DMSO was used as a common solvent which dissolves
for both blocks, PLA and poly(Asp). The solution was then added dropwise into water
under vigorous agitation. Micelles were formed by the solvent affinity difference in a
selective solvent. Micelles were prepared according to the method mentioned in section
3.2.4. The hydrodynamic diameter by DLS and zeta potential showed ca. 130 nm and -38
mV, respectively, which reflected that the nanoparticles were surrounded by the ionic
poly(Asp) segment. Subsequently, a PEG-poly(Lys) aqueous solution was added
dropwise into the micelle preparations, and the newly formed micelle solution showed
the neutralization of the zeta potential -0.2 - 6 mV due to electrostatic interaction of
opposite charges. PEG served as an outermost shell which facilitated the stability and
solubility of nanoparticles in water. The hydrodynamic radius increased to ca. 300 nm,
which strongly suggested that encapsulation of the poly(Asp) surrounded ionic micelles
occurred. However, a large amount of aggregates was also observed by DLS, which
suggested low stability of the layered-micelle.
The effect of pH on micellar size was examined and plotted in Figure 3.7 (Top).
The inner micelle composed of PLA-poly(Asp) was the smallest at pH 7 at 0.02 wt%, and
its size increased as it became more basic and acidic. It was speculated that the size
increased as increasing charge repulsion from poly(Asp) when the pH of the solution was
not neutral, and the intermediate layer was susceptible to changes of environment such as
pH and salt concentration. After the addition of the outer polymer, PEG-poly(Lys),
micelles became unstable overtime and various sizes of micelles were observed.

62

Micelle size

inner micelle size at different pH
350
300
250
200
150
100
4

5

6

7

8

9

Micelle size (nm)

pH

1000
800
600
400
200
0
0

0.05

0.1

0.15

0.2

NaCl concentration (M)

Figure 3.7 Top: the pH of micelle solution on inner micelle size; Bottom: micelle size
variation based on salt concentration in water.
The effect of salt concentration on the micelle size was also tested. Previous
research suggested that the salt would compete with ionic charge and destabilize the
micelle.87 Polymers precipitated out of the micelle solution over various time periods in
response to varying salt concentrations. Overall, the micelle solution was stable for 5-6 h
at most. Figure 3.7 (Bottom) showed the stability was significantly affected by the
presence of salt. High salt concentration resulted in faster polymer precipitations. Water
insoluble polylactide would consequently precipitate out of the water solution. Thus,
micelle life span significantly reduced in saline solution at various concentrations.
Therefore, micellar stability was hard to maintain under physiological conditions. A
microscopic imaging system, AFM, was used to examine actual micellar size and shape,
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and it was found that the size of spherical micelles was around 300 nm as shown in
Figure 3.8.

Figure 3.8 AFM image analysis of micelle size of micelle design 2. Left: 4x4 µm; Right:
1x1 µm

3.3.3.4. Flower micelle formation

Figure 3.9 The second design of layered micelle.
Triblock copolymer, poly(Lys)-PEG-poly(Lys) was used to examine micelle
formation. PLA-poly(Asp) was able to form ionic micelles in DI water with a
hydrodynamic radius of 180 nm, and the zeta potential of -43 mV. Upon adding an equal
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molar charge of new triblock copolymer poly(Lys)8-PEG-poly(Lys)8, the resulted micelle
was slightly expanded to 190-220 nm in diameter, and the zeta potential was found to be
slightly positively charged. The neutralization of zeta potential indicated the electrostatic
interaction between charged polymers. The flower type micelles also experienced strong
interruption from salt content in the solution, which generated large aggregates (>1000
nm) and destabilized overtime.
3.3.3.5. Emulsion preparation
We observed the formation of nanoparticles with narrow micelle size distribution.
The negative zeta potential and neutralization of the particles were detected for the stage
of inner micelle preparation and the final micelle formation, respectively.
Thus far, nanoprecipitation method was used to prepare all micelles, in which
self-assembly of block copolymers was the driving force in the miscible selective solvent
systems. However, PLA-poly(Asp), actually included significant amounts of
homopolymers. Another mechanism for the formation of nanoparticles, oil-in-water (o/w)
emulsion system was examined. To prepare water soluble nanoparticle solutions, the free
poly(Asp) chains would serve as surfactants to stabilize the polylactide particle emulsion
in water. Then, PEG-poly(Lys) and poly(Lys) coat the ionized nanoparticle to form
micelles.
Unlike self-assembled micelle solution from the nanoprecipitation method,
described in the previous section, oil/water emulsion required high energy input to
prepare nanoparticles. PLA was dissolved in CHCl3, and it was added dropwise into
water containing poly(Asp) under a strong vortex. The resulting emulsion was
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subsequently homogenized for 10 seconds 3 times with an ultrasonic probe in an iced
bath after CHCl3 was evaporated. The solution was centrifuged, and precipitants were
removed. Poly(Lys)-PEG-poly(Lys) was added dropwise into PLA/poly(Asp) emulsion
solution under strong sonication. The hydrodynamic diameter of emulsion particles
obtained was ca. 185 nm without encapsulating the drug. Upon addition of poly(Lys)PEG-poly(Lys), the size of particles increased to ca. 250 nm. The particle size by
emulsion method were similar to those by nanoprecipitation.
3.3.3.6. Drug encapsulation
The capability of drug loading was evaluated. Prednisone and nabumetone were
chosen as model drugs for the encapsulation test because they were nonionic and poorly
water-soluble drugs. Due to hydrophobic properties, these drugs were difficult to disperse
under physiological conditions. Prednisone is a corticosteroid drug that is used for the
treatment of inflammatory diseases and it relieves symptoms by reducing immune system
responses. Nabumetone is an anti-inflammatory drug used for reducing pain associated
with arthritis.
Table 3.1 summarized the drug loading test results. The nabumetone encapsulated
PLA emulsion particles were around 230 nm; whereas the prednisone containing
emulsion had a diameter of 191 nm. A control study was conducted to compare the drug
loading capacity among PLA-nanoparticles (NP) via polyvinyl alcohol emulsion method,
PLA-PEG-PLA micelles, and micelle design 2. The nabumetone containing PLA-NP was
close to 300 nm. However, the nabumetone containing PLA-PEG-PLA micelle solution
contained mostly aggregates as determined by DLS. The prednison containing PLA-
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PEG-PLA micelle, however, contained mostly micelles with diameters of 20 nm. It was
found that the stability of emulsion was significantly reduced upon addition of poly(Lys)PEG-poly(Lys) solution. The PLA/poly(Asp) emulsion precipitated as the zeta potential
of the solution reached zero. The PLA-PEG-PLA micelle demonstrated great stability
measured by the DLS. The PVA emulsion was too large to be considered as effective
drug delivery vehicles; whereas polypeptide emulsion posed challenge to reduce to
comparable size as PLA-PEG-PLA micelle could. Overall, PLA-PEG-PLA micelles
could form smaller sized nanoparticles.
Table 3.1 Drug encapsulation comparison among emulsion, micelle, and micelle design 2
DLS before
centrifugation

Loading rate
(drug/PLLA weight
ratio)
(wt%)

(nm)

Loading efficiency
assumption
(encapsulated/feed 1mg)
(%)

P1

N2

P

N

P

N

PLLA o/w
emulsion

240

270

5.7

4.7

28

24

PLLAPEGPLLA
micelle

20

670

6.2

2.0

41

13

agg3

agg

nd4

nd

nd

nd

Micelle
design 2flower
micelle
1

Prednisone, 2Nabmetone, 3aggregates, 4not determined

Quantitative NMR analysis was conducted to confirm encapsulation efficiency of
the emulsion micelle particles shown in Table 3.1. The final supernatants of emulsion
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solutions were analyzed by NMR using a constant amount of NMR solvent. PLLA o/w
emulsion had a loading rate of 5.7% for prednisone; PLLA-PEG-PLLA micelles had
loading rate of 6.2% for prednisone. However, the loading rate of polypeptide emulsion
was unable to determine due to the large amount of aggregates presents. Thus, it
indicated the instability and low efficiency of drug encapsulation of the micelle-2 in
comparison of PLA-PEG-PLA micelle.
3.4. Conclusion
Two designs of polyionic complex micelles were prepared and their structure and
properties were examined. Poly(Asp) and poly(Lys) were synthesized as polypeptide
blocks using PLA and PEG macroinitiators, respectively. Both types of micelles
contained the same inner micelle made of PLA-poly(Asp) with hydrophobic PLA as a
core. These inner micelles showed negative zeta potentials, and the hydrodynamic radius
was in the range of 100-200 nm. For the outer layers, one micelle was coated with PEGpoly(Lys) and other one was coated with triblock copolymer poly(Lys)-PEG-poly(Lys).
However, both micelles were easily aggregated and unstable.
One major problem for the micelle behavior was attributed to the structural defect
of the block copolymers: the inner micelle was formed using a mixture of PLA,
poly(Asp), and PLA-poly(Asp) instead of only the diblock copolymer. Poly(Lys)
synthesis, on the other hand, required a demanding condition to prevent premature selfpolymerization. Thus, further research is needed to investigate micelle/emulsion using
poly(amino acid)s as practical drug delivery tools. Improvement of PLA-poly(Asp) could
be achieved by using the initiator with longer hydrocarbon chain for PLA synthesis to
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avoid the unwanted rearrangement between the amine group of the polymer terminal and
the nearest ester of the polymer backbone. The stability of micelle or emulsion could be
improved by introducing larger number of charged polypeptides. The study in this
chapter, however, proved the potential designs of PIC multilayered micelles for
biocompatible, pH responsive, and/or chemically tagged drug delivery systems.
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Chapter 4
Conclusion and Outlook
The studies described in this dissertation focus on the development of
multilayered micelles and hydrogels for drug delivery using two different designs. One of
the systems was a DNA loaded, three-layered micelle (3LM) prepared from two triblock
copolymers, PLA-PEG-PLA and PLA-PEI-PLA. The resulting micelle was composed of
an ionic complex at the core, and hydrophobic intermediate layer of PLA and hydrophilic
corona of PEG. 3LM showed improved stability and pH-triggered DNA release. An
injectable hydrogel was prepared using 3LM and PDLA-PEG-PDLA triblock copolymer
micelles by the chain-exchange stereocomplexation at physiological temperature. The
resulting hydrogel had relatively strong moduli and a stable structure. The degradation of
the hydrogel showed that the gel was stable within the pH-neutral environment and
degraded in an acidic solution. In vitro preliminary studies showed promising transfection
and gene expression at target cells. Corresponding solid-state NMR and WAXS data
showed that the 3LM hydrogel was driven by PLA stereocomplexation, and the
crystallinity provided stability and shielded the drug from premature release.
The second system was to use polypeptides to formulate 2 different micellar
designs. The design concept revolved around using polypeptide copolymers to form the
multilayered micelles through the electrostatic interactions of poly(amino acid)s.
However, the polymerization of NCA cyclic monomers terminated prematurely due to
side reactions at elevated temperature. This complication resulted in the synthesis of
relatively short polymer chains. Block copolymers, PEG-poly(Lys), poly(Lys)-PEG-
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poly(Lys), and PLA-poly(Asp) were prepared for micelle formation. One of the major
drawbacks was a structural defect of the block copolymers: PLA-poly(Asp) contained a
mixture of PLA, poly(Asp) and PLA-poly(Asp). Poly(Lys), on the other hand, required a
demanding anhydrous environment. Thus, the study of micelle/emulsion would be more
informative with well-prepared polymers for practical drug delivery. Improvement of
PLA-poly(Asp) could be achieved through longer hydrocarbon chain as the initiator to
distance the number of carbon between free amine and the a nearest ester moiety. The
stability of micelles or emulsions could be improved by introducing a larger number of
charged polypeptides. Although the encapsulation properties was not optimized for drug
delivery, fundamental understandings of poly(amino acid) chemistries including
monomer stability and polymerization reactivity, and their micelle properties such as size
and stability in aqueous solution were obtained. In summary, a 3LM hydrogel has shown
to have potential as local drug delivery system for gene therapy. Whereas DDS vehicles
using poly(amino acid)s could still be challenging but would improve with right choice of
amino acids combination and their copolymer design.
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